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CHAPTER 1- INTRODUCTION TO ERCC1 IN DNA REPAIR AND ITS POTENTIAL
UTILITY IN PREDICTING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
IN LUNG CANCER

1.1 THE ERCC1 GENE AND GENE PRODUCTS
A variety of human diseases can be attributed to defects in proteins that are involved
in DNA repair and genome maintenance. These diseases can generally be segregated
into three categories, 1. Diseases associated with developmental or neurological deficits;
2. Diseases associated with premature aging, 3. Diseases related to cancer
susceptibility. Some of these diseases related to mutations in DNA repair genes include
Xeroderma

Pigmentosum,

Ataxia

Telangiectasia,

Fanconi

Anemia,

Cockayne

Syndrome, Cerebro-Oculo-Facial Syndrome, Bloom Syndrome, as well as a variety of
cancer predispositions (1-5). In general, the genetic mutations associated with these
diseases lead to loss of function or decreased functionality of the gene products that
contributes to the accumulation of DNA damage, mutation, or telomere shortening and
together these effects lead to anemias, premature aging, neurological deficits, and/or
cancer.
Efforts to understand the underlying mechanisms contributing to these diseases with
functional loss of various DNA repair pathways could lead to new therapies for treating
these rare diseases as well as contribute to possible new treatments for cancer. A
hallmark of cancer is increased genome instability which allows cells to actively adapt to
various pressures (including immune, tumor-microenvironment, and drug-induced
pressures) thereby supporting tumor cell growth (6). In support of the hypothesis that
mutations in DNA repair genes may support these processes, a large number of tumors
harbor defects in DNA repair genes or factors that indirectly influence DNA repair,
including ERCC1, BRCA1, BRCA2, ATM, among many others. By some estimates, up to
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50% of all lung cancers harbor mutations in DNA repair genes conferring phenotypes
similar to BRCA1/2 mutations supporting the importance of studying the role of
functional loss of DNA repair and genome stability in promoting tumor formation, growth,
drug resistance, as well as for novel drug development and biomarker-driven clinical trial
design (7). Because of this weakness in tumor cells, substantial scientific effort is being
made to understand the mechanistic basis underlying these tumor-specific DNA repair
deficiencies and to find novel ways to exploit these DNA repair deficiencies selectively in
tumors while sparing normal cells.
One critical DNA repair factor that is often altered at the mRNA and protein levels in
lung and ovarian tumors is the protein Excision Repair Cross Complementation Group 1
(ERCC1). ERCC1 forms a constitutive heterodimer with its protein partner, Xeroderma
Pigmentosum Group F (XPF) (8). Together these proteins form a structure-specific 5’ –
3’ endonuclease which plays multiple critical roles in a number of DNA repair pathways
including Nucleotide Excision Repair (NER), Interstrand Crosslink Repair (ICL-R),
Homologous Recombination (HR), and Single Strand Annealing (SSA) as well as a
number of specialized cellular functions including in gene imprinting (8-11). ERCC1 was
first functionally identified in 1984 in complementation experiments in a UV-sensitive
Chinese hamster ovary cell line where expression of ERCC1 could complement the UV
sensitivity observed indicating that ERCC1 was involved in repair of UV-induced DNA
damage, including thymine dimers and cyclobutane dimers, and ultimately provided
evidence that mutations in ERCC1 could be associated with the disease Xeroderma
Pigmentosum (12). The ERCC1 gene is located on chromosome 19 at the cytogenetic
band 19q13.32. The ERCC1 gene is composed of 9 coding exons and the predominant
splice variant of ERCC1 consists of 297 amino acids (Figure 1.1) (13). Many important
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Figure 1.1 Structure of ERCC1 isoforms and protein-protein interaction domains.
Cartoon illustrates the gene structure of ERCC1 isoforms and currently available
antibodies for detection of ERCC1. Reproduced with permission from Friboulet et al.
New England Journal of Medicine, 2013 (13), © Copyright Massachusetts Medical
Society.
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interaction domains have subsequently been identified in ERCC1 that are associated
with its cellular functions. Some of these key interaction domains include important
interactions with XPF, XPA, single strand DNA binding domain, and double strand DNA
binding domain (Figure 1.1) (13-15). These important functional domains will be
discussed further in 1.3.
Alternative splicing of the ERCC1 gene was first discovered in the mid-1990s and
there are currently four known protein-coding splice variants of ERCC1 in human cells
which are denoted as ERCC1-202, ERCC1-201, ERCC1-203, and ERCC1-204 (Figure
1.1) (13, 16). It is currently thought that ERCC1-202 is the only functional splice variant
involved in DNA repair. Each splice variant differs from ERCC1-202 by single exon
exclusion or intron inclusion (Figure 1.1). ERCC1-201 excludes exon 10 in favor of
inclusion of intron 9. ERCC1-203 excludes exon 8 and ERCC1-204 excludes exon 3.
The mechanistic basis for alternative splicing of ERCC1 remains undefined although a
report identified alternative splicing of ERCC1 can be controlled by certain types of DNA
damage that induce hyperphosphorylation of RNA Polymerase II (e.g. topoisomerase I
poisons) which theoretically leads to inclusion or exclusion of specific RNA splicing
factors (17).
While ERCC1-202’s roles in DNA repair are well known, functions for the other
three splice variants remain unknown. A previous report provided evidence that ERCC1203 mRNA levels were negatively associated with activity in Nucleotide Excision Repair
(16). Thus, it was postulated that ERCC1-203 could be dominant-negative to ERCC1202 activity. However, the evidence for this hypothesis is conflicting as work by Friboulet
et al. did not identify any differences in sensitivity to the DNA crosslinking agent cisplatin
between A549 ERCC1 knockout cells re-expressing ERCC1-202 and dual ectopic e-

5

expression of ERCC1-202 with ERCC1-201, -203, or -204 (18). The authors only
observed rescue from cisplatin sensitivity with re-expression of ERCC1-202, suggesting
that ERCC1-202 is the only variant functional in DNA repair (18). However, this does not
entirely rule out the possibility that ERCC1-203 could negatively regulate ERCC1-202
function by means independent of ectopic re-expression of ERCC1-202. Importantly,
Friboulet et al. discovered that only ERCC1-202 was capable of interaction with its
protein partner XPF, indicating that alternative splicing of ERCC1 may impact protein
folding in such a way as to block the interaction of ERCC1 splice variants with XPF (18).
Very little is currently known about ERCC1-201 function in cells. Currently available
information suggests that it is non-functional in Nucleotide Excision Repair and
Interstrand Crosslink Repair (13, 18). Furthermore, it is incapable of interaction with XPF
as well as with another NER factor, XPA (18). Until recently, it was thought that ERCC1204 was also completely non-functional in DNA repair and that it could not interact with
XPF as described in Friboulet et al. (18). In the development of antibodies specific to the
ERCC1/XPF heterodimer and subsequent co-immunoprecipitation experiments, it was
identified that ERCC1-204 (which retains the entire XPF binding domain) could interact
with XPF, which may suggest it has roles in promoting DNA repair or preserving genome
stability (19). The lack of effect of ERCC1-204 on sensitivity to DNA crosslinking agents
may support the idea that ERCC1-204/XPF has more specialized, non-essential roles in
DNA processing and there is evidence that XPF endonuclease activity is involved in
some specialized DNA processing events (20). Subsequent studies focused on
identifying functions for ERCC1-204 in genome stability would benefit from exploring
potential functions independent of ERCC1’s canonical roles in NER and ICL-R.
1.2 CRITICAL PHYSICAL INTERACTION BETWEEN ERCC1 AND XPF
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Key to ERCC1’s functions in DNA repair is its heterodimeric interaction with the
protein XPF (8, 21, 22). This constitutive interaction is not only critical for XPF’s
nuclease activity during DNA repair but is also essential for ERCC1 and XPF protein
stability (22). Similar to the yeast homologues of ERCC1/XPF, Rad1 and Rad10 (21,
23), this protein heterodimer forms a 5’-3’ structure specific endonuclease (8, 24). After
ERCC1’s discovery in 1984, it was discovered that Rad1 and Rad10 formed a
heterodimer and possessed intrinsic endonuclease activity (23, 25-27). Shortly thereafter
ERCC1’s heterodimer was definitively identified as the Xeroderma Pigmentosum protein
XPF (8, 28). This early work also showed clearly that activity of purified ERCC1/XPF
activity was similar to Rad1/Rad10 in terms of DNA cleavage of a specific in vitro DNA
substrate (8, 24). ERCC1 and XPF interact through their C terminal HhH2 domain and it
is generally thought that this interaction leads to proper protein folding which is required
for stability (15, 29). While it is thought that ERCC1 and XPF require each other for
protein stability and/or proper protein folding, the effects on stability of XPF with loss of
ERCC1 may be more severe than the effects on ERCC1 stability with loss of XPF (3032). Thus, it is still unclear whether ERCC1 absolutely requires XPF for protein folding in
all circumstances or whether its folding/stability is only partly reduced when XPF is
depleted. In addition, it was recently observed that in some instances XPF can selfdimerize and stabilize itself in biochemical assays, however it is unclear whether these
XPF homodimers are actively formed in vivo and whether they possess any functionality
(33).
1.3 THE ROLE OF ERCC1 IN DNA REPAIR
1.3.1 NUCLEOTIDE EXCISION REPAIR
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Nucleotide Excision Repair (NER) is a DNA repair pathway tasked with removing
bulky ssDNA adducts from DNA. These bulky lesions are all similar in that they distort
the DNA helix, although different lesions vary in the extent of helical distortion. As a
result, this pathway contributes to the removal of a wide range of DNA adducts. In
general, these types of lesions include those caused by UV light, endogenous reactive
aldehydes, lesions induced by various environmental exposures (including metals), and
a subset of those caused by various chemotherapy agents including cisplatin and
mitomycin C. While NER as a DNA repair pathway is conserved from prokaryotes to
humans, eukaryotic NER (i.e. from yeast to humans) is quite distinct from prokaryotic
NER with limited homology between prokaryotic and eukaryotic NER factors (34, 35).
The bacterial NER system is rather simple with a requirement for very few proteins
including UvrA, UvrB, UvrC (the endonuclease component, which has a distinct catalytic
domain from the eukaryotic NER endonuclease XPF) and DNA helicase II (35). On the
other hand, eukaryotic NER requires a larger set of factors including those involved in
DNA damage recognition, repair scaffolding proteins, and DNA endonucleases (34). The
increased complexity of eukaryotic NER is likely due to evolutionary changes in
eukaryotic genomes including substantial increases in genome size (including
heterochromatic and euchromatic regions), limited genome copy number, more complex
genome structure and architecture, as well as a dramatically longer cell cycle. A number
of proteins are involved in NER in humans including, XPA, XPB, XPC, XPD, XPF, XPG,
ERCC1, DDB1, DDB2, CSA, CSB, RPA1, RPA2, CETN2, LIG1, MMS19, RAD23A,
RAD23B, TFIIH complex, and XAB2 (although this is not an exhaustive list of all
accessory proteins involved in human NER) (34).
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Two general pathways for NER exist in yeast and mammalian NER including
Global-Genomic NER (GG-NER) and Transcription-Coupled NER (TC-NER) (34). The
main difference between these two NER pathways is whether the DNA damage is
encountered in the presence or absence of the transcriptional machinery (Figure 1.2). In
GG-NER, damage is initially recognized by the protein XPC in conjunction with the
factors CETN2 and RAD23B (36, 37). Depending on the extent of the helical distortion
induced by the lesion, XPC-DNA binding may also require involvement of the damage
recognition complex UV-DDB (containing DDB1 and DDB2) which promotes the binding
of XPC to the DNA (38, 39). For lesions inducing small distortions, UV-DDB is generally
involved in GG-NER. For lesions that cause greater helical distortions, XPC can directly
bind to the DNA but this process may also involve UV-DDB in some cases. Binding of
XPC to the DNA promotes recruitment of the TFIIH complex (including XPB and XPD)
where the complex’s helicase activity is essential for creating a DNA bubble composed
of two ssDNA regions flanked by dsDNA regions on the 5’ and 3’ side (40, 41). While
one strand of the ssDNA is bound by TFIIH complex, the complementary strand of
ssDNA is bound by the ssDNA binding protein RPA (42). Once the DNA bubble is
formed the DNA is primed for incision by the 5’- 3’ DNA endonuclease ERCC1/XPF and
the 3’-5’ endonuclease XPG. This process is influenced by the presence of RPA as well
as

the

scaffolding

protein

XPA

which

help

to

recruit

ERCC1/XPF

and

coordinate/stimulate nucleolytic incisions by ERCC1/XPF (through direct interaction with
ERCC1) and XPG (42-45). After two incisions, one by ERCC1/XPF and a second by
XPG, a short, excised DNA is produced that is generally ~17-32 nucleotides in length
(46). DNA replication across the ssDNA gap occurs following incision by ERCC1/XPF
and involves PCNA, Replication Factor C, as well as a DNA polymerase (34). DNA
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Figure 1.2 Model of Global
Genomic and TranscriptionCoupled
Nucleotide
Excision Repair. Reprinted
with permission from Springer
Nature.
Marteijn
et
al.
Understanding
Nucleotide
Excision Repair and its roles
in cancer and aging. Nature
Reviews
Molecular
Cell
Biology. 2014. © Springer
Nature.
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replication is ultimately followed by DNA ligation stimulated by DNA Ligase I or XRCC1DNA Ligase 3 (34).
TC-NER differs from GG-NER in that it is coupled to the transcriptional
machinery. TC-NER may be critical for less distorting DNA lesions that may possess
slow kinetics of removal from the DNA. When a bulky single-stranded lesion interferes
with normal transcription, TC-NER is activated by stalled RNA Polymerase II (47).
Stalling leads to recruitment of two key factors, CSA and CSB (48, 49). Additionally, the
initial factors involved in TC-NER, CSA and CSB, likely aid in the removal of other types
of DNA damage not generally repaired by NER including oxidative base damage
(Reviewed in (34)). Thus, TC-NER is likely more complex in terms of DNA repair
pathway choice, however, the mechanisms for CSA- and CSB-mediated repair and
repair pathway choice is incompletely understood. In other words, the TC-NER pathway
is likely not a process specifically devoted to NER, but rather a broader, transcriptionlinked DNA repair pathway that possesses inherent flexibility in terms of which
downstream DNA repair pathway undergoes subsequent activation. Recruitment of
these factors is critical for further recruitment of the NER machinery. Because RNA
Polymerase II is a large complex of proteins, movement of RNA Polymerase II can be
essential for physical exposure of the bulky adduct for efficient processing by TC-NER.
One way that movement of the polymerase can be accomplished in order to facilitate
repair is via physical reversal of theRNA polymerase on the DNA, although the specific
mechanism for reversal of the RNA polymerase on the DNA is not fully understood (50).
Upon recruitment of CSA and CSB to the site of the bulky DNA lesion and physical
reversal of the RNA polymerase II, TC-NER converges with GG-NER by leading to the
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recruitment of the core NER factors described above, including the DNA endonuclease
ERCC1/XPF.
1.3.2 INTERSTRAND CROSSLINK REPAIR
Interstrand crosslinks (ICL) constitute a specific type of DNA lesion which
involves linkages between nucleotides in opposing strands of DNA. ICLs can be induced
by a variety of endogenous and exogenous chemicals, including reactive aldehyde
species and various types of chemotherapies. In fact, ICL-inducing agents have been
widely utilized for cancer therapy since the 1940s and these agents include nitrogen
mustards, platinum-based compounds, and mitomycin C. While often initially effective,
toxicity and resistance remain substantial clinical limitations to the long-term success of
ICL-inducing agents. ICLs distort the DNA helix to different extents depending upon the
agent and the DNA sequence at which binding occurs and this helical distortion can aid
in detection of ICLs (51). Additionally, if left unrepaired these lesions can block
replication and transcription, induce replication fork collapse, and activate cellular
pathways involved in cell cycle arrest and apoptosis (52).
ICLs require several DNA repair pathways for ultimate removal and repair of the
DNA damage. Also, the specific repair pathways responsible for interstrand crosslink
repair differ by the cell cycle phase in which the lesions are encountered. In G 1 phase, it
is generally thought that NER is the major pathway involved in removal and repair of
ICLs, although a Mismatch Repair-mediated ICL repair mechanism was recently
described in extracts from Xenopus laevis (53). The major difference between NER in
removal of single strand adducts vs. ICLs is that a second set of incisions mediated by
ERCC1/XPF and XPG must occur to fully remove the ICL from both strands of DNA
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Figure 1.3 Models of Replication-Coupled Interstrand Crosslink Repair. Reprinted
from “Mechanism and regulation of incisions during DNA inter-strand crosslink repair,”
DNA Repair, Vol 19, Zhang and Walter, pp. 135-142, © Copyright 2014, with permission
from Elsevier.
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(54). In G1 phase where this mechanism would be relied upon, there is general
consensus that there exist no known endonucleases capable of compensating for loss of
ERCC1/XPF ultimately implying that ERCC1/XPF activity is absolutely essential for ICL
repair in G1 phase.
While ICLs can be repaired during G1 phase, it is generally thought that most
ICLs are encountered during S phase (55). During S phase, ICL-R is much more
complex where ICL-R involves several nucleolytic incisions and DNA repair pathways
including the Fanconi Anemia (FA) and HR machineries (56). In general, the initial
processing of the ICL (i.e. double strand break formation) depends on the type of
replication fork that stalls (57). Depending on the state of the replicated DNA at the fork
and whether the fork has a replisome on one or both sides of the ICL, this creates
varying structures capable of being nucleolytically cleaved by endonucleases to produce
a DNA double strand break (57). There are currently three models for incisions at an
ICL that depend on the nature of the replication fork: a single fork model, convergent fork
model and replication traverse model (Figure 1.3) (57). The earliest model is the single
fork model, the next model to be postulated was the convergent or dual fork model, and
the most recently described model is the replication traverse model. All these models
likely represent actual structures encountered during S phase in living cells. Recent
evidence suggests that the single fork model accounts for approximately 20% of all ICLs
encountered (58). The dual-fork model accounts for approximately 15% of all ICLs
encountered (58). Finally, and somewhat surprisingly, replication traverse represents
approximately 55% of all replication events at ICLs (58). This was surprising because
ICLs were thought to act as complete replication blocks because there was no known
mechanism for replication bypass of ICLs which would require either lesion bypass by
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the DNA polymerase or unloading and reloading of the replicative CMG helicase.
Furthermore, replication is tightly controlled in cells and so it is unclear how the CMG
helicase could be reloaded onto the DNA in order to allow DNA replication to continue.
Despite the gaps in knowledge, what is unique to each model is the type of DNA
structure formed. Five nucleases have been described to play roles in interstrand
crosslink repair, including ERCC1/XPF, EME1/Mus81, SLX1/SLX4, Fan1, and SNM1A.
Elegant studies in Xenopus extracts showed in a dual-fork model that ERCC1/XPF
activity was critical for incision of an ICL substrate (59). It was also discovered that
ERCC1/XPF acted in conjunction with the scaffolding protein SLX4 to facilitate incision
at an ICL (59). SLX4 is an important master regulator of endonuclease recruitment
during replication coupled ICL repair and is known to interact with the endonucleases
ERCC1/XPF, EME1/Mus81, and SLX1 (57). Furthermore, ERCC1/XPF activity is linked
to activation of the FA pathway where localization of ERCC1/XPF and SLX4 to the site
of the ICL in a dual fork model is dependent upon the FA core factor, FANCD2 (59). As
another layer of complexity, it was recently shown that ERCC1/XPF incision at the site of
an ICL in living cells may require RPA loading which is similar to the requirement for
RPA to stimulate XPF incision during NER (60). In this model, RPA loading adjacent to
the ICL activates ERCC1/XPF activity which in turn leads to recruitment of the SNM1A
nuclease which can physically digest past the ICL (60).
Initial observations were made in NER mutant cells that ERCC1/XPF defective
cells were more sensitive to ICL-inducing agents than cells that harbored mutations in
other NER factors. This suggested that ERCC1/XPF could have additional roles in the
repair of ICLs independent of NER (61-63). Work from Kuraoka et al. was the first to
clearly show that ERCC1/XPF was indeed involved in ICL-R independently of its NER
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function, where ERCC1/XPF was capable of incising near an ICL in a synthetic ICLcontaining DNA substrate in vitro (10). To this day, the regulation of which DNA
endonucleases cleave which substrate and at what time remains incompletely
understood. For example, work from Niedernhofer et al. showed that double-strand
break formation during ICL-R was independent of ERCC1/XPF and that resolution of
these double strand breaks required ERCC1/XPF activity (55). That observation at first
seem incompatible with a requirement of ERCC1/XPF activity for the initial incision steps
at ICLs. However, considering the number of potential ICL repair models, it is possible
that in the absence of ERCC1, the bulk of ICLs are incised by other endonucleases
including Mus81 whose preferred substrate is formed during replication fork traverse and
Slx1 and Fan which might prefer those structures formed at single fork structures (57).
The recent discovery that replication fork traverse may be the predominant model
for replication at ICLs combined with the understanding that the structures formed during
this process are ideal for cleavage by Mus81 appear to support the idea that
ERCC1/XPF activity is likely important for multiple steps during ICL-R including the initial
incision steps and during resolution of HR intermediate structures since the cleavage
product produced via Mus81 cleavage would produce a structure that would likely
require ERCC1/XPF 5’ endonuclease activity to facilitate HR completion (55, 64). This
hypothesis would better support the observation that ERCC1/XPF deficient cells are
more sensitive to ICL-inducing agents than other ICL-R endonucleases. In 2008,
Bergstrahl and Sekelesky boldly postulated that ERCC1/XPF activity was not required
for ICL unhooking and that its most important roles during ICL-R occurred downstream
of the initial processing events (65). The evidence appears to support this idea: if dual
fork models of ICL-R (ideal substrates for ERCC1/XPF activity) only account for
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approximately 15% of all ICLs encountered in replicating cells, this would be inconsistent
with hypersensitivity to ICLs beyond other endonucleases, particularly Mus81 which may
provide the initial cleavage step at up to 60% of ICLs in vitro.

Thus, the role of

ERCC1/XPF in resolving complex ICL repair intermediate structures during HR may be
critical for supporting cell viability after exposure to ICL-inducing agents. Indeed, recent
work has shown that Mus81-mediated cleavage at sites of DNA harboring secondary
structures such as G quadruplexes or AT-rich stem loops requires ERCC1/XPF activity
to cleave the 3’ overhangs to facilitate HR (64). It is interesting to speculate whether
processing of a platinum-DNA adduct during ICL-R would create a structure in which
ERCC1/XPF activity is essential for cleaving 5’ to the ICL in order to allow HR to be
completed. In line with this hypothesis, ERCC1/XPF is known to interact with Slx4 which
is known to be involved in binding to branched DNA structures formed during HR such
as the one that would be formed during HR of a substrate containing an (partially)
unhooked platinum-DNA adduct.
Once initial processing occurs at ICLs, it is generally thought that there is
activation of the HR machinery to facilitate repair of the DNA DSB that is produced by
ICL unhooking. This process would entail the traditional components of HRR including
displacement of RPA coated ssDNA by Rad51 which is mediated by BRCA2, strand
invasion, DNA polymerization, followed by ligation (Reviewed in (66)). Additionally, HR
repair of ICL-induced DNA damage likely requires at least three additional nucleolytic
events at multiple steps beyond ICL unhooking: one incision would be required to
completely unhook the ICL from one strand of DNA (3’ flap structures containing bulky
DNA damage), two additional incisions would be required to remove the ICL from the
complementary strand of DNA (mediated by NER?), and additional incision steps may
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be necessary to resolve intermediate structures during HR. However, these intermediate
structures have been difficult to define and thus, the roles of ERCC1/XPF in downstream
processing of HR repair intermediates are unclear except to state that ERCC1/XPF
activity appears to have essential, significant roles in processing of HR intermediates
(resolution of Holliday junctions/cleavage of 3’ flaps) during HR-mediated repair of ICLs
(64, 67).
1.3.3 SINGLE STRAND ANNEALING
Aside from the role of ERCC1/XPF activity in NER and ICL-R, ERCC1/XPF has
essential roles in error-prone mechanisms of double strand break repair, including
clearly defined roles in Single Strand Annealing (SSA) independent of any clearly
defined roles in Microhomology Mediated End Joining (MMEJ) (i.e. Alternative EndJoining) which is another error-prone pathway for DNA DSB repair (9, 68, 69). SSA is an
error-prone double strand break repair pathway that is conserved from yeast to
mammals (70). In general, it relies upon sequences containing greater than 100 base
pairs of homology near a double strand break to promote repair with a non-homologous
sequence of DNA (i.e. a sequence different than that found on the sister chromatid)
which ultimately promotes ligation, resolution of the double strand break, and loss of
genetic information (70). A DNA double strand break can be shuffled into Homology
Directed Repair during S and G2 phase or into Non-Homologous End Joining (NHEJ) in
any phase of the cell cycle. However, under some contexts which remain unclear,
double strand breaks can be repaired via the SSA repair pathway. It is likely that under
certain circumstances there may be DSBs that are not compatible with HRR or NHEJ
and so SSA plays an important role in limiting the persistence of DNA DSBs.
Alternatively, SSA may be a backup repair pathway that functions when an otherwise
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HRR- or NHEJ-compatible DSB is not repaired via these pathways. Unique from DSBs
repaired via NHEJ where Ku70/Ku80 proteins limit end resection in an attempt to limit
genomic instability, SSA relies on DNA end resection to expose homologous sequences
adjacent to the DNA DSB that can be utilized for annealing to a short, homologous
sequence in a generally unrelated region of DNA (70). Upon annealing of the short,
homologous sequence, the non-homologous 3’ tail of DNA is cleaved by endonucleases
(ERCC1/XPF), a DNA polymerase synthesizes DNA across the gap, and ligation occurs
to ultimate resolve the DSB (70).
SSA annealing relies upon a conserved set of proteins including phosphorylated
CtIP and the absence of recruitment of factors that limit DNA end resection including
53BP1 (68, 71, 72). The necessity of CtIP for SSA suggests that this pathway is
generally only active during S/G2 phase of the cell cycle because CtIP phosphorylation is
necessary for its roles in promoting DNA end resection and exposure of homologous
DNA sequences and its phosphorylation which is controlled by cyclin-dependent kinases
is generally limited to S/G2 phase of the cell cycle (72-75). This is an important event
because during S/G2 phase where the sister chromatid is present, DNA end resection is
an important aspect of HR. Conversely, during G1 phase where the sister chromatid is
not present, end resection could lead to dramatic losses in genetic information, thus for
NHEJ-mediated repair of DNA DSBs, DNA end resection is not required and is actively
suppressed (72). In this context, DNA end resection is not only critical for repair of DNA
DSBs through HR, but also is important for SSA and MMEJ suggesting that these
pathways may generally be most active during S/G2 phases of the cell cycle. Upon
resection and exposure of the homologous sequence, this substrate is capable of being
annealed to the donor which is mediated by the protein Rad52 (76). After annealing, the
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next step in repair is endonucleolytic cleavage of the 3’ ssDNA overhangs formed during
the annealing process. This process is mediated by ERCC1/XPF endonuclease activity
which is stimulated by Rad52 (77). Finally, the resulting gaps are ligated by a DNA
ligase. Further evidence for the role of Rad52 and ERCC1/XPF nuclease activity in SSA
is supported by the observation that the yeast homologues of these factors, Rad52
(hBRCA2 and hRad52) and Rad1/Rad10, also play essential roles in SSA annealing in
yeast (78).
There are several major differences between SSA and MMEJ. The first major
difference is the length of the homologous sequence utilized for annealing. MMEJ can
be performed with homologous sequences as short as 1-16 nucleotides while SSA
usually has sequences of homology generally longer than 100 nucleotides (e.g.
repetitive sequences of DNA in the genome) (79). A second major difference between
MMEJ and SSA is the amount of DNA resection that occurs (70, 79). For MMEJ, this
resection is rather limited while extensive resection generally occurs at breaks that
undergo SSA (70, 79). This makes sense considering that less resection would be
required to expose a homologous sequence of 1-16 nucleotides while more extensive
resection would be required to expose a homologous region of greater than 100
nucleotides. One could also hypothesize that this might impact the recruitment of
specific DNA repair factors and alter the specificity for cleavage of the 3’ overhangs by
endonucleases. A final major difference between these two pathways are the key DNA
repair factors that mediate each repair pathway. While SSA strongly relies upon Rad52
function, Rad52 function is not required for MMEJ (68). Conversely, PARP and Pol
activity are essential for MMEJ repair, but not for SSA (80-85). Although the importance
of these factors for MMEJ remains unclear, some have postulated that PARP may be
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critical for recruiting Pol to displace RPA, promote annealing likely in conjunction with
Rad52, and promote extension of the DNA in order to stabilize the microhomologous
DNA sequences which can be 1 - 16 nucleotides (79, 82). Together these data support a
hypothesis in which SSA plays an important role in eukaryotic DNA repair leading to its
being evolutionarily conserved from yeast to humans.
1.4 PLATINUM-BASED CHEMOTHERAPY
1.4.1 CISPLATIN
Platinum-based antineoplastic agents were first discovered in the 1960s by Barnett
Rosenberg at Michigan State University. Rosenberg was investigating how magnetic
and electrical fields impacted cellular division in bacteria. While investigating how
electrical fields impact cell division, E. coli were grown in medium with platinumcontaining electrodes and subsequently exposed to an electrical current (86). The
results from these experiments showed that the bacteria were incapable of dividing until
after the electrical current was removed. However, subsequent work identified platinumcontaining compounds that leached from the platinum electrodes as being responsible
for inhibiting cell division (87). It was out of these follow-up studies that the compound
cisplatin (cis-diamminedichloroplatinum(II)) was first discovered (87). Further work
investigated the potential of utilizing cisplatin to inhibit tumor growth utilizing a murine
sarcoma model (88). These early in vivo studies showed that cisplatin was capable of
inhibiting tumor growth and could even be curative against murine sarcoma. Eventually,
cisplatin entered clinical trials and was subsequently FDA approved in 1978 (52).
Platinum-based chemotherapy remains a mainstay for cancer treatment over 50
years since its original discovery and is often given as first-line treatment in combination
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Figure 1.4 Structure of platinum-based antineoplastic agents. Reproduced from (91)
(Todd and Lippard. Metallomics. 2009) with permission from The Royal Society of
Chemistry
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with a second cytotoxic agent or in combination with immunotherapy. It remains widely
used for the treatment of a variety of human cancers including lung, ovarian, head and
neck, testicular, bladder and cervical cancers and nearly 50% of all cancer patients will
receive a platinum-based agent during the course of treatment (89). Platinum-based
therapy even has curative potential when given in combination with other cytotoxic
agents in testicular germ cell tumors which until the advent of cisplatin remained a
devastating disease with few treatment options (90).
Cisplatin is structurally a very simple compound containing a platinum atom with
two cis NH3 groups and two cis chloride groups bound to the platinum (Figure 1.4) (91).
In the blood stream where chloride concentrations remain high (~100 mM), these
chloride molecules remain intact and cisplatin remains inert (92, 93). However, upon
entry into the cell where chloride concentrations are much lower (~3 – 20 mM), cisplatin
undergoes two aquation reactions where two water molecules displace the chloride
atoms to form a monoaquated platinum and subsequently a diaquated platinum
molecule (92-94). Upon the aquation reactions, cisplatin becomes a biologically active
molecule (94). Platinum-based drugs inhibit tumor cell growth by inducing DNA, RNA,
and protein damage, but it is generally accepted that the main cause of its antitumor
effects is via its binding to DNA (52, 95, 96). Cisplatin is capable of binding at multiple
sites on purines in the DNA, but it’s up to four orders of magnitude more reactive for
guanine than for adenine (97). Together this means that platinums mainly function by
binding to guanines in the DNA, specifically to the N7 position of guanine (97).
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Figure 1.5 Structure of platinum-DNA complexes. A. Structure of a cisplatin 1,2
d(pGpG) adduct. B. Structure of a cisplatin 1,3 d(pGpTpG) adduct. C. Structure of a
cisplatin interstrand crosslink. Reproduced from (91) (Todd and Lippard. Metallomics.
2009) with permission from The Royal Society of Chemistry
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Cisplatin can form three distinct types of lesions on the DNA including
monoadducts (platinum bound to a single base on a single strand of DNA), ISAs
(platinum bound to two bases on a single strand of DNA), and ICLs (platinum bound to
two bases on opposing strands of DNA). Monoadducts are generally formed in low
abundance after cisplatin treatment (<5%) and evidence suggests that monoadducts do
not inhibit DNA synthesis which might suggest that monoadducts in low abundance have
limited toxicity (91, 98, 99). ISAs are the most abundant type of cisplatin-DNA lesion
formed and they can constitute up to 90% of all lesions formed (92, 100, 101). These
lesions are generally of three types including d(pGpG), d(pGpXpG) (where X represents
adenine, thymine, or cytosine), and d(pApG). Formation of d(pGpG) adducts represents
approximately 65% of all adducts formed by cisplatin, while the d(pGpXpG) and d(pApG)
adducts represent approximately 25% and 5-10% respectively (91). These ISAs are
bulky lesions that distort the DNA helix in different ways and are capable of blocking
DNA synthesis and inhibiting transcription even if the lesion is located on the non-coding
strand of DNA (91, 98, 102). For example, a d(pGpTpG) adduct induces localized
unwinding of the DNA double helix and bends the duplex DNA ~ 30o, while a d(pGpG)
adduct leads to a more substantial bending of the duplex DNA at 60-70o (Figure 1.5 A
and B) (91). Finally, formation of G-G ICLs crosslinks is a relatively rare event and these
lesions constitute 1-8% of all platinum-DNA lesions (91, 103). The structures induced by
platinum-DNA ICLs are unique from those induced by ISAs. ICLs formed by cisplatin
induce bending of the DNA helix by ~47o and induce localized unwinding which leads to
adjacent cytosines (cytosine that were initially paired with the guanines that became
crosslinked to the platinum) being extrahelically flipped from the DNA helix (Figure 1.5
C) (91, 104, 105). Due to the relative abundance of ISAs relative to ICLs, some have
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speculated that the ISAs are the likely abundant source of toxicity induced by cisplatin
(reviewed in (93)). While this hypothesis makes sense, there is still debate in the field as
to what the general contribution of ISAs vs. ICLs is to cytotoxicity as a whole.
Cisplatin is in opposition to transplatin which was also discovered in Rosenberg’s
initial experiments (87). Transplatin consists of two trans chloride groups and two trans
NH3 groups. Even though the chloride groups also undergo two aquation reactions, the
structure of transplatin limits its ability to form intrastrand adducts (ISAs), while it can still
form monoadducts (106). While these monoadducts can be converted to interstrand
crosslinks in biochemical assays utilizing synthetic DNA substrates, the kinetics of this
reaction are exceedingly slow (t1/2 > 24 hours) and thus, transplatin has greatly reduced
biological activity compared to cisplatin (106, 107). It is thought that the steric
hinderance caused by the trans amine groups in transplatin likely limits the types of
lesions that transplatin can form. While some have postulated that transplatin is capable
of forming ISAs at d(pGpXpG) sites, other have postulated that in double stranded
DNAs, these ISAs actually lead to formation of ICLs (106). Finally, other groups have
suggested that transplatin forms no ICLs while only forming a minimal number of ISAs
(106). The determination of what type of DNA lesions are formed by transplatin is likely
an academic exercise as transplatin displays virtually no biological activity.
1.4.2 CARBOPLATIN
Cisplatin is a highly toxic drug with many patients experiencing nephrotoxicity,
myelosuppression, and neuropathy. Due to this fact much effort has been made to
develop new platinum-based drug analogues that are either more selective for tumor
tissue or less toxic. This is especially important for patients who may be particularly
susceptible to toxicities associated with cisplatin including those with comorbidities or in
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older patients. Since the advent of cisplatin, a number of structural analogues have been
developed preclinically and several entered into clinical trials in the United States and
around the world with two of these platinum analogues receiving FDA approval,
including carboplatin and oxaliplatin. The most widely used of these platinum analogues
is carboplatin, which was FDA approved in 1986. Structurally, carboplatin has a
cyclobutane dicarboxylate group in place of the two chloride groups found in cisplatin
(Figure 1.4). While carboplatin is structurally distinct from cisplatin, upon aquation it
becomes identical to the biologically active form of cisplatin as only the chemical leaving
groups differ between the two. While both cisplatin and carboplatin form the same DNA
lesions, carboplatin has been widely used due to its reduced toxicity profile. Although the
DNA lesions induced by carboplatin are identical to cisplatin, the kinetics of DNA adduct
formation differ slightly based upon the length of time that is required for removal of the
cyclobutane dicarboxylate leaving group (94). Knox et al. were among the first to show
that the chloride leaving groups of cisplatin are much more labile as compared to the
cyclobutane dicarboxylate group on carboplatin meaning that aquation of cisplatin
occurs with faster kinetics by nearly two orders of magnitude compared to carboplatin
(94). This difference in reaction kinetics also means that DNA lesions are formed with
faster kinetics in the presence of cisplatin compared to carboplatin (94).
1.4.3 OXALIPLATIN
A second platinum analogue known as oxaliplatin is also widely utilized in the clinic
and was approved by the U.S. FDA in 2002. Its clinical appeal was that it had an even
further reduced toxicity profile compared to cisplatin and carboplatin (108-110).
Additionally, its use is generally restricted to older patients or those with comorbidities for
whom the toxicities of cisplatin or carboplatin would be prohibitive. A number of studies
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have consistently shown similar performance of cisplatin or carboplatin compared to
oxaliplatin in a number clinical studies with beneficial toxicity profiles in the oxaliplatin
treated arms of these studies (108-110). Subsequently, an oxaliplatin-containing
regimen did become FDA approved for first-line treatment of metastatic colorectal
cancer patients in 2004 and showed superiority to the previous standard of care, 5Fluorouracil/Leucovorin (111, 112). However, in many other cancers oxaliplatin use still
remains restricted to those not capable of tolerating cisplatin or carboplatin treatment.
Oxaliplatin is structurally distinct from cisplatin even upon aquation and forms structurally
distinct DNA lesions, although with lower efficiency than cisplatin (91, 113). While
oxaliplatin induces fewer total lesions than cisplatin, some of these lesions may in fact
be more cytotoxic than those induced by cisplatin as oxaliplatin was shown to be more
effective than cisplatin at inhibiting DNA replication (113).
1.4.4 OTHER PLATINUM ANALOGUES
This subsequent section is by no means an exhaustive list of platinum-based
compounds currently undergoing preclinical or clinical development which was reviewed
in (114). However, several other platinum analogues and platinum formulations
(including liposomal) have been developed which showed promise in preclinical studies.
Satraplatin was first developed in 1993 and it is structurally distinct from cisplatin,
carboplatin, and oxaliplatin in that it is based upon Pt4+ as opposed to Pt2+ (91, 115).
Another major difference from the FDA approved platinum analogues which are all given
intravenously is that satraplatin can be administered orally (115, 116). 17 clinical trials
are listed for satraplatin in clinicaltrials.gov with 16 trials having been completed or
terminated. The only current active clinical trial with satraplatin is based in China.
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Satraplatin failed to meet its endpoint in Phase III clinical trials in castration-resistant
prostate cancer and it appears that further clinical development has been halted.
Another platinum analogue known as picoplatin showed promising preclinical
results (117). It is structurally similar to cisplatin, carboplatin, and oxaliplatin in that it is
based upon Pt2+ (117). Like cisplatin it has two cis chloride molecules. While it also has
a single amine group, it structurally differs from cisplatin by the addition of a 2methylpyridine group (117). It was thought that the addition of this bulky ring structure
helped the drug to avoid neutralization by thiol groups intracellularly (114). Additional
preclinical studies showed that picoplatin was capable of overcoming resistance to
cisplatin, carboplatin, and oxaliplatin in platinum-resistant cell line models (118, 119).
Aside from in vitro studies, in vivo studies were also promising in ovarian tumor models
(117). Picoplatin entered into Phase I and ultimately into Phase II clinical trials in several
cancers including in non-small cell lung cancer as first-line therapy and in small-cell lung
cancer as second-line therapy in patients previously treated with platinum-based
chemotherapy (120). Picoplatin failed to meet its primary endpoint and had limited
effects on inhibiting tumor progression (120). As such, picoplatin is not currently
undergoing further therapeutic evaluation.
1.4.5 ROLE OF NER IN RESISTANCE TO PLATINUM-BASED CHEMOTHERAPY
A major limitation to the use of platinum-based agents in cancer therapy is the
presence of intrinsic or acquired resistance. Platinum-based agents are often given as
first-line therapy in a number of tumor types, including lung cancers. However, a subset
of patients will not respond to treatment and these tumors are defined as intrinsically
resistant. Alternatively, many patients whose tumor responds to platinum-based
chemotherapy initially, will ultimately acquire resistance to these agents and no longer
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respond. Many mechanisms of resistance to platinum-based chemotherapy have been
described including increased NER, increased translesion synthesis, loss of mismatch or
base excision repair (BER), decreased apoptotic potential, and increased platinum
inactivation or reduced platinum accumulation which have been reviewed in (52, 92,
121, 122). Tumors generally display widespread clonal heterogeneity and it is likely that
in most instances resistance does not occur on a global level, but rather treatment
selects for clones that are intrinsically resistant to therapy.
Because the lesions induced by cisplatin are up to 90% intrastrand adducts
which are repaired via the NER pathway, increased NER is thought to be a predominant
mechanism of resistance to platinum-based chemotherapy. By increasing the rate of
removal of platinum-DNA lesions, this would decrease the amount of time that intact
lesions can activate the DNA damage response and stimulate cellular apoptotic
pathways and ultimately reduce the therapeutic window for treatment. In support of this,
there is a general inverse correlation between expression of NER factors and sensitivity
to cisplatin both in vitro and in retrospective patient studies (123-128). NER as a
mediator of platinum resistance has been widely studied in the context of in vitro, in vivo,
and patient-based studies. One key NER factor that has been widely studied in the
context of platinum resistance/sensitivity in multiple tumor types including non-small cell
lung, ovarian, bladder, and head and neck cancer is ERCC1. In the studies referenced
above, increased ERCC1 expression is generally associated with increased resistance
to platinum-based chemotherapy. Conversely, low ERCC1 is associated with prolonged
survival after platinum treatment. As part of the ERCC1/XPF endonuclease which is
generally required for removal of platinum-DNA ISAs and ICLs, dysregulated ERCC1
expression is thought to be a biomarker for predicting responders and non-responders to
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platinum-based treatment. Somewhat counterintuitively, high ERCC1 expression in
early-stage lung cancers is associated with increased overall survival (129, 130). This
may indicate that in early stage disease, high ERCC1 promotes genome stability and
thus contributes to less aggressive disease, while in advanced disease which is
associated with increased genomic instability and mutation burden high ERCC1 is
associated with therapy resistance which in turns supports tumor growth. Due to this
relationship between increased NER and resistance to platinum-based chemotherapy,
various NER factors have become potential targets for therapeutic development,
including XPA, ERCC/XPF, RPA (131-137). Some of these small molecule inhibitors of
NER factors are currently undergoing further preclinical development.
1.5 ERCC1 AS A BIOMARKER FOR PLATINUM RESPONSE
The expression of ERCC1 and its correlation to sensitivity to DNA crosslinking
agents aside from those formed by UV light began to emerge in the early 1990s. In
patient tumors, initial evidence was provided in 1992 that ERCC1 mRNA expression was
2.6-fold higher in tumors from ovarian cancer patients who were resistant to platinumbased chemotherapy (138). This observation was confirmed in a later study from the
same group utilizing ovarian cancer tissue (139). These data pointed to the possible role
for ERCC1 expression in mediating response to platinum-based chemotherapy. In vitro
evidence that ERCC1 expression may be associated with sensitivity to DNA crosslinking
agents was published in 1991 in the context of nitrogen mustards, which at the time was
a commonly used treatment for various types of leukemias (140). Additional evidence
was published that ERCC1 was involved in mediating resistance to other DNA
crosslinking agents commonly used in cancer therapy including mitomycin C and
cyclophosphamide (63, 141, 142). In relation to ERCC1-mediated cisplatin resistance,
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in 1993 and 1994 two papers were published directly implicating ERCC1 in mediating
repair of cisplatin-induced DNA damage (143, 144). Early studies implicated ERCC1
expression as being potentially important for regulating cisplatin cytotoxicity in cell lines
and patient tumors, and biochemical analyses showing ERCC1/XPF is physically
involved in processing of cisplatin-DNA ISAs and psoralen ICLs were published in 1994,
1996, and 2000 (10, 145, 146). Furthermore, it was identified that after cisplatin
treatment, ERCC1 expression increases due to increased stimulation of ERCC1
transcription (but not ERCC4/XPF transcription) mediated by c-Fos and c-Jun,
downstream mediators of Ras/MAPK signaling (147). Indeed, the Ras/MAPK pathway
has been associated with increased ERCC1 expression in cancer cell lines likely due to
increased transcriptional activity via two AP-1 sites in the ERCC1 promoter (148-150).
Since these first observations, data has continued to accumulate over the last 25 years
establishing ERCC1 expression as a bona fide marker of cisplatin sensitivity/resistance.
The first clinical evaluation of the impact of ERCC1 tumoral expression on patient
survival was published in 1998 in gastric cancer where patients with low ERCC1 mRNA
expression responded better to combination fluorouracil/cisplatin than those with high
ERCC1 mRNA expression (151). During the early 2000s, ERCC1 and its clinical
potential for predicting response to platinum-based chemotherapy began to blossom. In
2001, a retrospective patient study once again identified ERCC1 mRNA expression as a
predictor of overall survival in response to platinum-based chemotherapy in gastric
cancer (152). In 2002, a subsequent study identified low ERCC1 mRNA expression was
associated with increased overall survival in non-small cell lung cancer patients with
advanced disease receiving a regimen of platinum and gemcitabine (153). Additional
follow-up studies (including a Phase II clinical trial) in non-small cell lung cancer
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validated these observations with ERCC1 mRNA expression as well as by protein
expression as measured by immunohistochemistry (123, 154-156). However, these
results showing low ERCC1 corresponds with better response to platinum-based
chemotherapy were not always consistent between studies from different research
groups (157, 158). While most clinical studies utilized ERCC1 mRNA expression as the
means

for

quantifying

ERCC1

expression,

there

were

efforts

to

utilize

immunohistochemistry-based approaches to quantify ERCC1 protein which was thought
to be a better predictor of tumoral expression of ERCC1 than mRNA (123). However,
subsequent studies proposed that the antibody utilized in that study was not appropriate
for immunohistochemical detection of ERCC1 and actually bound a second antigen,
namely CCTα (159, 160). A subsequent study showed that there were inherent problems
with the antibody used in those clinical studies, specifically problems pertaining to batchto-batch variability that ultimately impacted the predictive nature of IHC-based ERCC1
quantitation in terms of clinical response to platinum-based chemotherapy (13). A
second problem with the IHC-based studies is the lack of specificity for the functional
ERCC1 isoform (ERCC1-202). In other words, ERCC1 quantification via IHC could
artificially inflate the number of ERCC1 positive tumors and impact patient stratification,
although recent studies have confirmed that IHC-based quantification of ERCC1 is
predictive of overall survival in ovarian cancers (13, 18, 127). While these issues have
become well known, there have been efforts made to create antibodies specific for
ERCC1/XPF heterodimer to circumvent problems with ERCC1 splice variant expression
(19).
Use of ERCC1 as a potential first-in-class platinum response biomarker began to
gain traction in the field of non-small lung cancer partly because of the limited efficacy of
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this therapy. Thus, identifying a biomarker that would predict (non)responders to therapy
could lead to the identification of patients that would be ideal responders (i.e.
personalized/targeted therapy) and could aid in the development of novel therapies to
treat those who do not respond to platinum-based chemotherapy (161, 162). While
preclinical data showing that ERCC1 expression was promising in multiple studies, a
prospective international, randomized Phase III clinical trial in non-small cell lung cancer
failed to show benefit for patients with low ERCC1 who received a platinum agent (163).
1.6 CENTRAL HYPOTHESIS
Many in vitro preclinical studies investigating ERCC1-deficiency as a predictive
marker for cisplatin sensitivity clearly showed that low ERCC1 is associated with better
response to cisplatin. While many retrospective clinical studies also corroborated results
from in vitro studies, an international, randomized Phase III study failed to show benefit
for patients with low ERCC1 who received a platinum agent. Together, these data
suggest that there remains an incomplete understanding regarding the biological
relationship

between

ERCC1

expression

and

sensitivity

to

platinum-based

chemotherapy in the patient setting. With this in mind, we hypothesized that confounding
biological variables exist that may have impacted previous studies investigating ERCC1
as a platinum biomarker. Furthermore, we hypothesized that better understanding how
ERCC1 expression is associated with sensitivity to DNA crosslinking agents could lead
to an improved understanding as to how best to select for patients that would benefit
specifically from a chemotherapy regimen containing a platinum agent. To address these
hypotheses, this study investigated the following specific aims.
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Aim 1: Investigate the role of p53 status in modulating sensitivity of ERCC1deficient cell lines to DNA crosslinking agents.

Aim 2: Explore the potential of utilizing the ATR inhibitor, M6620, to overcome
platinum tolerance in ERCC1-deficient cells.
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CHAPTER 2- IDENTIFICATION AND CHARACTERIZATION OF SYNTHETIC
VIABILITY WITH ERCC1 DEFICIENCY IN RESPONSE TO DNA
CROSSLINKS IN LUNG CANCER

This chapter has been reprinted with modification from Heyza et al. Clinical Cancer
Research. 2019 with permission from the American Association for Cancer Research
© AACR 2019

2.1 Introduction
The structure-specific endonuclease excision repair cross-complementation
group 1 (ERCC1)/xeroderma pigmentosum group F (XPF) plays key roles in nucleotide
excision repair (NER), interstrand crosslink repair (ICL-R), homologous recombination
(HR) repair, and single-strand annealing pathways. Although the role of ERCC1/XPF in
NER is well established, the totality of its specific functions in the processing and repair
of interstrand crosslinks (ICL) has remained unclear (see refs. (65, 164) for review). ICLs
are produced upon exposure to agents that covalently link bases in opposing strands of
DNA, and endonucleases are required for cleavage of the phosphodiester backbone
adjacent to ICLs in order to initiate repair (54). Much recent evidence indicates
ERCC1/XPF is required for ICL-unhooking, whereas other work highlights additional
roles for this complex in ICL-R downstream of unhooking (55, 59, 62, 165).
Use of interstrand crosslinking agents, including cisplatin, remain a mainstay in
the treatment of malignancies. Several mechanisms for resistance to platinum-based
chemotherapy have been described, including loss of base excision repair and mismatch
repair, decreased drug accumulation, increased sequestering by thiols, decreased
apoptosis, and increased translesion synthesis (52, 166-168). Another proposed
mechanism of resistance to cisplatin involves increased expression of ERCC1/XPF
observed both in vitro with cisplatin-sensitive/resistant cell lines and in relation to survival
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in patient samples (123, 153-155, 168-170). Work by our laboratory and others have
shown that downregulation of ERCC1/XPF sensitizes cancer cells to cisplatin and that
this sensitivity is related to a reduction in ICL and intrastrand adduct (ISA) repair (31). In
addition, small molecule inhibitors of ERCC1/XPF can increase cisplatin sensitivity both
in vitro and in vivo, indicating the potential of pharmacologically targeting ERCC1/XPF to
enhance platinum efficacy (135, 137).
First identified as a potential biomarker for response to platinum-based
chemotherapy in the late 1990s, low ERCC1 expression was observed in a relatively
high amount of patient tumors including in non–small cell lung cancers, head and neck
cancers, and ovarian serous adenocarcinomas. Although preclinical data were
promising, many challenges faced the clinical implementation of ERCC1 as the first
platinum biomarker including problems with antibody specificity, splice variant
expression, and conflicting results from clinical and preclinical studies. However, it is
possible that an incomplete understanding of basic biological factors controlling
sensitivity to ICL-inducing agents in the absence of ERCC1 may also have contributed to
the failure of the ERCC1 clinical trials. What has become clear over the past 10 years is
that a DNA-repair deficiency does not necessarily predispose to sensitivity to a particular
drug. This is most notably observed with BRCA1/2 deficiencies in the context of PARP
inhibition where loss of subsequent secondary factors is capable of making BRCA1/2mutant tumors resistant to PARP inhibition. In the context of ICL repair, recent evidence
has shown that loss of p53, the deubiquitinase, USP48, or the BLM–RMI1–TOPIIIa
signaling axis is capable of increasing resistance of Fanconi anemia (FA) deletion
mutants to ICLs both in vitro and in vivo (171-173). In particular, these findings directly
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implicate increased reliance on DNA repair pathways to deal with ICLs that would
otherwise be unrepaired as a result of loss of canonical ICL-R.
In this study, we identified p53 status as at least a partial modifier of the
sensitivity of ERCC1 knockout () cells to ICL-inducing agents. Here, we characterize a
panel of ERCC1 lung cancer cell lines developed with CRISPR-Cas9. We describe a
differential phenotype in sensitivity to cisplatin and mitomycin c (MMC) that appears to
be correlated with p53 status where ERCC1/p53WT cell lines exhibit hypersensitivity to
ICL-inducing agents, but ERCC1/p53mutant/null cells exhibit only mild sensitivity. Finally,
we show evidence that tolerance to interstrand crosslinks with ERCC1 deficiency is
supported by entry into S-phase and relies on BRCA1 and DNA-PKcs function. Together
this evidence suggests that functional loss of p53 may allow for the uncovering of
alternate repair mechanisms capable of at least partially overcoming the repair defects
associated with loss of ERCC1/XPF activity thus leading to the identification of a new
subset of cisplatin-tolerant, ERCC1-deficient tumors. These findings have direct clinical
ramifications for future studies of ICL-repair in human tumors as well as impacting any
attempts to implement biomarkers for sensitivity to ICL-inducing agents in the future.
2.2 Materials and Methods
2.2.1 Cell lines and cell culture
H1299, H460, H522, H1703, H1650, H358 were all obtained from the ATCC,
were tested for mycoplasma, and authenticated by the BioBanking and Correlative
Sciences Core Facility at Karmanos Cancer Institute. A549 WT and ERCC1 cells were
obtained from Jean-Charles Soria, Ken Olaussen, and Luc Friboulet (Gustave Roussy
Cancer Center). OV2008 and C13* cells were obtained from Stephen B. Howell
(University of California San Diego). A549 and OV2008 cells were not further
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authenticated or tested for mycoplasma. Cell lines were maintained for no greater than
15 passages during the course of experiments. H1703, H522, H460, OV2008, C13*,
H1650, H358, and H1299 cells were cultured in RPMI1640 (Dharmacon) media
supplemented with 10% FBS (Atlanta Biologicals) and 1% penicillin/streptomycin
(Dharmacon) and grown at 37 oC in 5% CO2. A549 cells were cultured in DMEM
(Dharmacon) supplemented with 10% FBS, 1% penicillin/ streptomycin, 1% MEM,
nonessential amino acids (Dharmacon), and 1% HEPES (Dharmacon).
2.2.2 CRISPR-Cas9–mediated gene knockout (Method adapted from (135))
Cas9-lentivirus was produced using the Lenticrispr V2, pVSVg, and psPAX2
plasmids (Addgene) in HEK293T cells. The day following seeding, cells were transduced
for ~16-hours with Cas9 lentivirus. Cells were selected with puromycin and clones were
selected using standard methods for ERCC1 knockout experiments. Cas9 expression in
selected clones was assessed by western blot and a high-expressing Cas9 clone was
chosen for ERCC1 knockout experiments. For all other knockout experiments, pooled
Cas9-expressing cells were used for subsequent transfection steps. Synthetic tracrRNA
and crRNA was purchased from Dharmacon. Transfection was performed as per the
manufacturer’s protocol. The day before transfection 150,000 - 300,000 cells were
seeded in antibiotic-free RPMI media. The following day synthetic RNA was diluted to a
100 µM stock in a 10 mM Tris pH 7.4 buffer containing nuclease-free water. A final
concentration of 50 nM was used for both tracrRNA and crRNA and was transfected with
3 µg/mL Dharmafect Duo Transfection Reagent (Dharmacon) in a total reaction volume
of 2.4 mL in a six-well plate format. Cells were transfected for 48 hours after which
complete media was added for 24 hours. Cells were seeded for clones and clones were
selected using standard methods. Clones were initially screened for knockout by
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western blot. Validation of genome editing was performed by PCR amplification of
genomic DNA with Taq polymerase (NEB). PCR product was cloned into a linearized
pCR4-TOPO vector and transformed into OneShot TOP10 E. coli using the TOPO-TA
Cloning Kit for Sequencing (Thermofisher). Bacterial colonies were selected with
ampicillin and plasmid was extracted using standard procedures. Plasmid was
sequenced by GeneWiz using an M13R primer. Knockout clones were validated by
Sanger sequencing excluding second ERCC1 knockout clones and the XPA knockout
clones which were validated by western blot.
crRNA sequences:
ERCC1 #1: 5’ AGGGACCUCAUCCUCGUCGA 3’
ERCC1 #2: 5’ AUCACAAAUUUCUUCCUUGC 3’
ERCC4: 5’ GCCAUGGCAAUCCGUCGAGC 3’
TP53: 5’ CCGGUUCAUGCCGCCCAUGC 3’
XPA: 5’ UGCUCUAAAGCCGCCGCCUC 3’
2.2.3 Colony survival assays
Colony survival assays were performed as previously described (166). Cells
were treated with cisplatin (Sigma-Aldrich) or MMC (Selleckchem) for two hours or
gemcitabine (Selleckchem), camptothecin (Selleckchem), or etoposide (Selleckchem) for
four hours in serum-free medium. Cells were treated with Palbociclib (Selleckchem),
Ribociclib (Selleckchem), DNA-PK inhibitor (NU-7441; Selleckchem), or XL-413 (DBF4dependent kinase inhibitor; Tocris) for 24 hours in complete medium. For UV-C
treatment, 2,000 cells were seeded in six-well plates and treated with the corresponding
UV-C dose the following day. Plates were fixed and stained with crystal violet three days
posttreatment and crystal violet was dissolved in 10% acetic acid and absorbance at 595
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nm was measured using a SpectraMax M5 plate reader (Molecular Devices). IC50s were
estimated using SigmaPlot 10.0 Software.
2.2.4 Viability assays
A total of 12,000 cells were seeded in 24-well plates. Cells were treated with
cisplatin for 24 hours and allowed to grow for an additional 24 hours. Live/dead cells
were counted using Trypan Blue exclusion and ~100 cells were counted for each
concentration.
2.2.5 Flow cytometry
Apoptosis was measured by flow cytometry using the PE Annexin V Apoptosis
Detection Kit (BD Biosciences). Cell-cycle profiles were determined using the propidium
iodide (PI) Flow Cytometry Kit (Abcam). For both assays, 5 x 105 cells were seeded in
10 cm plates. The following day cells were treated with 500 nmol/L cisplatin for two
hours in serum-free medium and cells were allowed to grow for 48 hours (for apoptosis)
or were collected at various time points (cell cycle). Flow cytometry was performed on a
BD LSR II SORP Flow Cytometer (BD Biosciences). Data were analyzed using ModFit
LT (Verity Software House) and FlowJo v10 (FlowJo, LLC).
2.2.6 Modified alkaline comet assay
Modified alkaline comet assays were performed essentially as previously
described (135, 166, 174). Cells were seeded in six-well plates so that they would be
70% to 90% confluent at the time of harvesting. H522 and H1299 cells were treated with
cisplatin for two hours. Control and cisplatin-treated cells were then treated with 100
mol/L H2O2 (Fisher Scientific) for 15 minutes immediately prior to harvesting by
trypsinization at 0, 24, and 48 hours post-cisplatin treatment. Cells were embedded in
0.5% low-melting agarose (Fisher Scientific; Catalog No. BP165-25) and spread on
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slides coated with 1.5% Standard Low–mr Agarose (Bio-Rad; Catalog No. 162-0100)
and allowed to solidify. After 10 minutes, slides were placed in 4 oC lysis buffer (2.5 M
NaCl, 100 mmol/L EDTA, 10 mmol/L Tris base, 1% Triton X-100, pH 10) for one hour.
Excess buffer was removed and slides were placed in the electrophoresis tank with 4 oC
alkaline electrophoresis buffer (0.3 mol/L NaOH, 1 mmol/L EDTA) and incubated for 20
minutes. Slides were electrophoresed for 25 minutes at 300 mA (22–26 V). Slides were
then incubated with 4 oC neutralization buffer (0.4 mol/L Tris Base, pH 7.5) for 10
minutes. Slides were fixed in 95% ethanol for 10 minutes and allowed to dry followed by
incubation

with

SYBR-Gold

(Invitrogen).

Slides

were

imaged

with

a

Nikon

epifluorescence microscope. Approximately 50 cells were analyzed per slide with Komet
Assay Software 5.5F (Kinetic Imaging). ICLs were measured as the ratio of the median
tail moment of the treated compared with the untreated sample where the ratio at 0
hours post-cisplatin treatment was normalized to 100% for each isogenic cell line.
2.2.7 Patient survival analysis
The Cancer Genome Atlas (TCGA) provisional lung adenocarcinoma cohort was
utilized to assess the relationship of ERCC1 tumor expression and TP53 mutational
status on patient outcomes (175, 176). Tumor genomic and patient outcomes data were
accessed for these TCGA patients on cBIOportal (176, 177). Genomic data were
cleaned and normalized prior to release as described previously (175, 176). ERCC1
expression was stratified into two groups, high and low, at the upper quartile of
expression values. TP53 mutation status was also stratified into two categories, mutated
or wild-type (WT), based upon the presence or absence of nonsynonymous mutations in
the coding region of the gene as detected by whole-exome sequencing. Patient overall
survival (OS) was modeled in R (version 3.4.3) using the Kaplan–Meier method and log-
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rank test. Because treatment data for the TCGA lung adenocarcinoma cohort is not
publicly available, we also analyzed the 2017 TCGA ovarian cancer data set. Patients
with stage 3 or 4 disease who received a platinum agent were included in the analysis.
Patients were selected based upon the presence or absence of a TP53 mutation and
patients were stratified based upon ERCC1 expression using the Affymetrix probe ID:
203720_s_at and the "auto select best cutoff" function. Data were analyzed using
KMPlotter (kmplotter.org/ovar/; (178)).
2.2.8 Immunofluorescence
Cells were seeded on coverslips and treated with 500 nmol/L cisplatin for two
hours. 48 hours posttreatment cells were fixed with 4% paraformaldehyde and
permeabilized in 0.3% Triton-X in PBS. Cells were blocked in 10% FBS in 0.1% Triton-X
in PBS for one hour and incubated with primary antibody for one hour and secondary
antibody for 1.5 hours in 1% BSA/0.1% Triton-X. DNA was stained with 300 nmol/L DAPI
for five minutes and coverslips mounted on slides with DakoCytomation Fluorescent
Mounting Medium (Agilent) and sealed with nail polish. Slides were imaged with a Nikon
epifluorescence microscope and images were analyzed using ImageJ software and the
Find Maxima function. A minimum of 100 cells per group per experiment were analyzed.
Antibodies are available in Table 2.1.
2.2.9 shRNA knockdowns and re-expression of p53 and ERCC1
BRCA1 and BRCA2 shRNAs were purchased as bacterial stocks from SigmaAldrich.
BRCA1 shRNA sequence: 5’ CCGGGAGTATGCAAACAGCTATAATCTCGAGATTATAG
CTGTTTGCATACTCTTTTG 3’
BRCA2 shRNA sequence: 5’ CCGGTACAATGTACACATGTAACACCTCGAGGTGTTA
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CATGTGTACATTGTATTTTTG 3’
ERCC1-202 cDNA was purchased from Genscript and was cloned into pCDH-puro
lentiviral vector. shRNA lentivirus and ERCC1-202 lentivirus was produced and
transductions were performed as previously described (179). TP53 cDNA was
purchased from Origene (Catalog No. R200003). Cells were transfected with 2.5
g/DNA per well with a final concentration of 3 g/well Lipofectamine for six hours. Cells
were allowed to rest for 24 hours, after which geneticin sulfate was added.
Approximately two weeks post-transfection, cells were harvested to assess p53
expression and experiments were performed. Knockdown of BRCA1 was validated by
western blot. BRCA2 knockdown was validated by quantitative real time polymerase
chain reaction (qRT-PCR) as described in Sawant et al. (174) using the following
primers:
Forward Primer: 5’ GTTGTGAAAAAAACAGGACTTG 3’
Reverse Primer: 5’ CAGTCTTTAGTTGGGGTGGA 3’
2.2.10 Statistical analysis for cell line studies
Flow cytometry and modified alkaline comet assay data were analyzed by twosample t test. Data comparing the dose effects of cisplatin or MMC on p53 status
stratified by ERCC1 WT and knockout were analyzed by two-way ANOVA with
interaction test. H2AX foci data were analyzed by Wilcoxon rank-sum test. Drug
response, apoptosis, and modified alkaline comet assay experiments were all performed
at least three times, unless otherwise stated. Cell cycle and H2AX foci formation
experiments are presented as a representative result from two to three individual
experiments.
2.2.11 Western blot analysis
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Protein extraction and Western blot analysis were performed as previously
described (174). Antibodies used for Western blot analysis are available in Table 2.1.
Table 2.1

2.3 Results
2.3.1 ERCC1 cells exhibit 2 distinct phenotypes upon cisplatin treatment
We developed a panel of ERCC1 cell lines using CRISPR-Cas9 to assess
differences in sensitivity to ICL-inducing drugs (Fig. 2.1 A). ERCC1 has 4 known splice
variants, which differ by single intron inclusion or single exon exclusion (13, 18), so in
order to generate a clean background for our studies, we designed a crRNA targeting
ERCC1 exon 2, which is shared by all ERCC1 splice variants. We utilized lung cancer
cell lines that differed in p53, EGFR, and K-Ras status (Fig. 2.3 A). As expected, loss of
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Figure 2.1. Cisplatin and mitomycin c sensitivity of a panel of ERCC1 lung cancer
cell lines. A. Western blot depicting ERCC1 and XPF expression in the WT and
ERCC1 cell lines generated by CRISPR-Cas9 and the A549 WT and ERCC1 cells. BC. Clustering of cisplatin clonogenicity assays of ERCC1 WT and ERCC1 cells by p53
status. D-E. Clustering of cisplatin viability assays of ERCC1 WT and ERCC1 cells by
p53 status. F-G. Clustering of MMC clonogenicity assays of ERCC1 WT and ERCC1
cells by p53 status. Data analyzed by two-way ANOVA. *** p<0.001.
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Figure 2.2 Clonogenic survival and viability after cisplatin treatment in ERCC1
wildtype and knockout cell lines. A. Clonogenic survival assays with cisplatin
treatment in p53 WT cell lines ± ERCC1. B. Clonogenic survival assays with cisplatin
treatment in p53-null and p53-mutant cell lines ± ERCC1. n = 3 independent
experiments plated in triplicate for each cell line. Data plotted as average of at least
three independent experiments ± SD. C. Viability assays with cisplatin treatment in p53
WT cell lines ± ERCC1. D. Viability assays with cisplatin treatment in p53-null and p53mutant cell lines ± ERCC1. n = 3 independent experiments plated in triplicate for each
cell line. Data plotted as average of at least three independent experiments ± SD.
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Figure 2.3 Cell line characteristics, secondary knockout clones and re-expression
of ERCC1-202. A. Cell lines utilized in the current study and status of p53, EGFR, and
K-ras are listed. Mutation status was obtained from Cosmic Database
(cancer.sanger.ac.uk) or cBIOportal (cbioportal.org) (except for H522 p53 status where
Sanger sequencing did not identify the homozygous deletion that was previously
reported. B. Western blot of additional ERCC1 clones in H460 and H1299 cells and the
XPF H1299 cells. Additional ERCC1 clones in this figure were validated by western
blot and the XPF clone was validated by sequencing. C-F. Colony survival assays of
additional ERCC1 and XPF clones. G-H. Western blot showing re-expression of
ERCC1-202 in H460 and H1299 ERCC1 cells. Colony survival assay shows increased
resistance to cisplatin with re-expression of ERCC1-202. n=3, plated in triplicate for each
colony assay performed in this figure. Error bars represent SD of the averages of all
experiments.
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ERCC1 led to loss of XPF expression, because both factors generally require each other
for loss of ERCC1 led to loss of XPF expression, because both factors generally require
each other for stability. However, a self-dimerization–based mechanism for XPF stability
in the absence of ERCC1 has been reported in biochemical studies and could explain
why one H1299 ERCC1 clone did not have reduced XPF expression (Fig. 2.3 B; (33)).
In addition, we received A549 ERCC1 cells for our investigations (Fig. 2.1 A).
Because ERCC1 is necessary for key aspects of NER, HR, and ICL-R, we
expected that ERCC1 loss would hypersensitize cells to cisplatin and MMC.
Interestingly, upon titration of cisplatin in clonogenic and viability assays, we saw two
distinct phenotypes, hypersensitivity and modest tolerance. H522, A549, and H460
ERCC1 (p53WT) cells were all very sensitive to cisplatin in both clonogenic (IC50s
ranging from 60 to 240 nmol/L) and viability assays (Fig. 2.2 A and C). These
observations were validated in a second ERCC1 clone in H460 cells which showed the
same hypersensitive phenotype (Fig. 2.3 B and C). Interestingly, loss of ERCC1 in
H1650, H1703, H358, and H1299 cells (p53null/mutant) only resulted in modest increased
sensitivity to cisplatin in clonogenic (IC50s ranging from 1.1 to 2.0 mol/L) and viability
assays (Fig. 2.2 B and D). These effects were validated with multiple ERCC1 clones
developed with two crRNAs, and a XPF clone in H1299 cells, suggesting this modest
sensitivity is a true phenotype of loss of functional ERCC1/XPF (Fig. 2.3 B, D-F). We
were able to fully restore resistance to cisplatin in H1299 ERCC1 cells and partially
restore cisplatin resistance in H460 ERCC1 cells when ERCC1-202 was re-expressed
(Fig. 2.3 G and H). We also observed this differential phenotype with MMC, a more
potent inducer of interstrand crosslinks than cisplatin (Fig. 2.4 A and B). Conversely, we
did not observe increased sensitivity of ERCC1 compared with ERCC1 WT cells with
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Figure 2.4. Clonogenic survival after mitomycin C treatment in ERCC1 wildtype
and knockout cell lines. A. Clonogenic survival assays with MMC treatment in p53WT
cell lines ± ERCC1. B. Clonogenic survival assays with MMC treatment in p53-null and
p53-mutant cell lines ± ERCC1. n=2, in triplicate for all colony survival assays with MMC
treatment. Error bars represent ± SD. C. Clonogenic survival assays of H460 and H1299
WT and ERCC1 cells with camptothecin treatment. n=3, in triplicate. Error bars
represent ± SD. D. UV-C sensitivity assays in H460 and H1299 WT and ERCC1 cells.
n=2, in triplicate. Error bars represent ± SD.
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Figure 2.5 Clonogenic survival after etoposide or gemcitabine treatment in ERCC1
wildtype and knockout cell lines. A. Sensitivity of parental and ERCC1 cells to
etoposide treatment in colony survival assays. n=2, plated in triplicate for each cell line.
Error bars represent ± SD. B. Sensitivity of parental and ERCC1 cells to gemcitabine
treatment in colony survival assays. n=2, plated in triplicate for each cell line. Error bars
represent ± SD.
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etoposide, gemcitabine or camptothecin in clonogenic assays, but both H460 and H1299
ERCC1 cells were sensitive to UV-C irradiation (Fig. 2.4 C and D; 2.5 A and B).
We observed that this differential phenotype appeared to be correlated with p53
status and so we performed clustering analysis based upon ERCC1 and p53 status. No
differential clustering was observed in ERCC1 WT cells stratified by p53 status in the
clonogenic survival or viability assays after cisplatin or MMC treatment (Fig. 2.1 B, D,
and F). However, plotting all ERCC1 cell lines together displayed two distinct
phenotypes that appeared to be correlated with p53 status, where p53WT/ERCC1 cells
were

significantly

more

sensitive

to

cisplatin

and

MMC

compared

with

p53mutant/null/ERCC1 cells (Fig. 2.1 C, E, and G).
2.3.2 Altering p53 status alters the differential sensitivity of ERCC1 cells to
cisplatin
The differential phenotype of ERCC1 cells to cisplatin and MMC appeared to be
correlated with p53 status, and we hypothesized that altering p53 status could alter or
reverse the observed phenotypes. To test this hypothesis, we overexpressed WT p53 in
the p53-null H1299 cell line and assessed clonogenic potential after cisplatin treatment
(Fig. 2.6 A; Fig. 2.7 A). We observed that expression of p53 in parental and ERCC1
cells increased sensitivity to cisplatin (WT: 4.4 mol/L vs. 2.3 mol/L and ERCC1: 1.3
mol/L vs. 0.4 mol/L; Fig. 2.6 A). To address whether loss of p53 could increase
tolerance of p53WT/ERCC1 cells to cisplatin, we utilized CRISPR-Cas9 to disrupt the
TP53 gene in H460 and H522 parental and ERCC1 cells using a crRNA targeted to
Exon 7 of TP53. Western blot analyses show loss of p53 in the H460 cell lines at steady-
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Figure 2.6 Effects of p53 on sensitivity of ERCC1 cells to cisplatin. A. Clonogenic
survival after cisplatin treatment in H1299 (p53-null and p53 re-expressed), H460 (p53
WT and knockout), and H522 (p53 WT and knockout) isogenic cell lines differing by p53
and ERCC1 status. n = 3; data plotted as average of 3 independent experiments ± SD.
B. Cisplatin viability assays of H460 and H522 isogenic cell lines treated with escalating
doses of cisplatin., n = 3; data plotted as average ± SD. C. Compilation of data for H460
and H522 cells from 3 independent flow cytometry experiments representing % AnnexinV positive cells ± single-dose cisplatin treatment. Data represented as average %
Annexin-V positive cells ± SD. *, p < 0.05 measured by 2-sided t test. NS, no
significance, p > 0.05.
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Figure 2.7 Western blots of p53 expression and sequencing results of p53
disruption by CRISPR-Cas9. A. p53 re-expression/disruption by CRISPR-Cas9 in
H1299, H460, and H522 cells. B. Clonogenic assay of H460 ERCC1 and
ERCC1/p53* cells fixed at Day 6 and Day 12. C. p53 disruption by CRISPR-Cas9 in
A549 cells. D. Clonogenic survival of A549 isogenic cells after treatment with cisplatin.
n=3, plated in triplicate for each cell line. Error bars represent ± SD. E. Sequencing
results of p53 editing in H460, H522, and A549 cells. F. Validation of ERCC1 in
OV2008 and C13* cells by western blot. G. Induction of p53 after cisplatin treatment. H.
Clonogenic survival of OV2008 and C13* cells after cisplatin treatment. n=2, plated in
triplicate for each cell line. Error bars represent ± SD.
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state levels and upon induction with Nutlin-3 (Fig. 2.7 A). In addition, we confirmed
disruption of TP53 by DNA sequencing (Fig. 2.7 E). In H460 ERCC1/p53* cells, we
observed modest increased clonogenicity (two-fold) after platinum treatment compared
with ERCC1 alone in shorter-duration colony assays (Fig. 2.6 A). This fold difference
could be dramatically enhanced (10-fold) by extending the length of the colony assay
from 6 to 12 days (Fig. 2.7 B). Despite reports that H522 cells harbor a homozygous
single-base deletion in codon 191 of the TP53 gene, we were not able to detect this
deletion when sequencing exons 5 and 6 of TP53. Therefore, for the purposes of this
study, we considered the H522 cell line p53 WT. The p53-edited H522 cell lines were
validated by sequencing which showed that the TP53 alleles were disrupted by CRISPRCas9 in the H522 p53* cells, including an 8 amino acid in-frame deletion in 1 allele which
would account for a slightly reduced molecular weight band near 50 kDa; we also
observed the acquisition of a truncated p53 mutant near 25 kDa (Fig. 2.7 A and E). In
H522 ERCC1 cells, TP53 was partially disrupted (Fig. 2.7 E). This would be consistent
with Western blot analysis results showing induction of p53 in the ERCC1/p53* clone
(Fig. 2.7 A). Partial TP53 disruption in H522 cells also resulted in increased colony
formation after cisplatin treatment in the ERCC1 cells (Fig. 2.6 A). Similar results were
also observed in A549 WT and ERCC1 cells upon TP53 disruption (Fig. 2.7 C-E).
We also assessed changes in viability of H460 and H522 isogenic cell lines with
increasing doses of cisplatin by Trypan Blue live/dead assays. Strikingly, we saw that
disruption of p53 in ERCC1 H460 cells increased the IC50 in viability assays >15-fold
(100 nmol/L vs. 1.8 mol/L; Fig. 2.6 B). In H522 cells, partial disruption of TP53 in
ERCC1 cells increased the IC50 in viability assays four-fold (0.8 mol/L vs. 3.3 mol/L;
Fig. 2.6 B). We also performed flow cytometry-based analysis of apoptosis with H460
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and H522 isogenic cells lines. All paired cell lines were treated for 24 hours with the IC 50
dose of the ERCC1 determined in the live/ dead assays and cells were allowed to grow
for an additional 24 hours before proceeding with flow cytometry. In H460 and H522
ERCC1 cells, cisplatin treatment resulted in approximately 50% cell death as measured
by the percent Annexin-V positive cells (Fig. 2.6 C). In ERCC1/p53* cells, loss of p53
conferred significant protection from cisplatin-induced apoptosis (Fig. 2.6 C). In addition,
the level of apoptosis observed in ERCC1/p53* cells was not statistically different from
p53* cells. These viability data appear to suggest that p53 loss is critical for limiting
apoptosis in the presence of unrepaired ICLs with loss of ERCC1.
Next, we tested whether knockout of ERCC1 had differential effects on cisplatin
sensitivity in the OV2008/C13* cell line model of cisplatin resistance. C13* cells exhibit
increased levels of ERCC1 compared with OV2008 cells (Fig. 2.7 F). Although both cell
lines possess WT p53, p53 induction in C13* cells is impaired and p53 is not stabilized
upon platinum treatment (Fig. 2.7 G; (180, 181)). In clonogenic assays, we observe
OV2008 ERCC1 cells are more sensitive to cisplatin than the C13* ERCC1 cells (Fig.
2.7 H). These data suggest that the differential phenotype may not be limited to p53
mutations but could be extended to include defects in p53 stability/induction.
2.3.3 Kinetics of the DNA damage response in ERCC1 cells
Our hypothesis regarding the role of p53 in this differential phenotype was that
p53 predisposed repair-deficient cells to apoptosis and that loss of p53 promoted DNA
damage tolerance. To assess general levels of DNA damage signaling in the ERCC1
cells, we performed a treatment time-course and measured levels of p53, CDKN1A
(p21), PARP1 cleavage, and H2AX phosphorylation at various time points by Western
blot analysis. In the cisplatin hypersensitive H460 and H522 ERCC1 cells, we saw
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induction of PARP cleavage after treatment, consistent with the viability assays (Fig. 2.8
A). In addition, we saw induction of p53 and p21 over time which persisted (Fig. 2.8 A).
Consistent with previously reported observations (55), we detected a large induction of
H2AX in the H460 and H522 ERCC1 cell lines which continued to the 48-hour time
point indicating persistent, unrepaired DNA DSBs in the hypersensitive cells (Fig. 2.8 A).
H1299 ERCC1 cells exhibited very little induction of cleaved PARP after treatment with
cisplatin (Fig. 2.8 A). Unexpectedly, there was very little induction of H2AX in H1299
ERCC1 cells compared with WT cells (Fig. 2.8 A), indicating either 1. DNA damage
signaling is defective, or that 2. DSB repair is not defective in these cells. The former
possibility is unlikely, considering cells defective in phosphorylation of H2AX are
sensitized to DNA damaging agents such as ionizing radiation (182-184). This evidence
suggests differential responses to DNA damage may contribute to the bimodal
phenotype observed in our panel of ERCC1 cells.
We further

confirmed

H2AX

results

from

Western

blot

analysis

by

immunofluorescence. In H460 WT cells, cisplatin treatment did not result in increased
H2AX foci formation 48 hours post-cisplatin treatment, whereas in ERCC1 cells foci
formation was dramatically increased (Fig. 2.8 B). These data would suggest that DSB
formation during ICL-R is at least partially independent of ERCC1/XPF activity. This
would be consistent with previous reports in ERCC1-deficient cells showing other
endonucleases are capable of the initial incision steps of ICL-R including Mus81 and
Fan1 (reviewed in (57)). In H460 ERCC1/p53* cells, we observed a significant
reduction in the number of H2AX foci present 48 hours after treatment (Fig. 2.8 B).
Conversely, in cisplatin-tolerant H1299 ERCC1 cells we observed very few H2AX foci
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Figure 2.8 Differential DNA damage signaling and interstrand crosslink repair in
ERCC1 cells. A. Western blot analysis of a cisplatin treatment time course measuring
induction of cleaved PARP, H2AX, p53, and p21 up to 48 hours in H460, H522, and
H1299 WT and ERCC1 cells. B. Images and quantification of one representative
experiment showing H2AX foci formation in H1299 and H460 cells 48 hours postcisplatin treatment. ****, P < 0.0001 as measured by Wilcoxon rank-sum test;
experiments performed 3 times. C. Modified alkaline comet assay data indirectly
measuring ICL-R in H522 and H1299 cells. Data presented as mean of 3 independent
experiments. Error bars represent SEM. *, p < 0.05 as measured by Student t test.
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at 48 hours post-cisplatin treatment likely suggesting that ICL-R is largely not defective
in these cells (Fig. 2.8 B).
Cisplatin is a bifunctional drug, which induces ISAs between guanine residues on
the same strand of DNA and these structures, which are repaired through NER,
represent >90% of the damage caused by cisplatin whereas ICLs represent
approximately 1% to 5% of total DNA adducts generated by cisplatin. We suspected that
ISAs, which should persist in ERCC1 cells, may be less toxic than ICLs which can
function as complete replication blocks. To tease apart whether the modest sensitivity
we observe in H1299 ERCC1 cells in clonogenic assays is due to unrepaired ISAs, we
generated XPA clones in H1299 cells (Fig. 2.9 A and D). XPA's only described function
is to act as a scaffolding protein during NER, and XPA-deficient cells are less sensitive
to MMC than ERCC1-deficient cells (61). So, XPA cells should display the relative
contribution of unrepaired ISAs in H1299 cells. In clonogenic assays, XPA cells display
the same sensitivity to cisplatin as ERCC1- or XPF-deficient cells, strongly pointing to
the modest sensitivity observed as the relative contribution of unrepaired ISAs (Fig. 2.9
B and E). We also measured sensitivity to MMC, which induces monoadducts and a
higher level of ICLs than cisplatin. We observed a classic phenotype, where ERCC1 and
XPF knockout cells were 2.5-fold more sensitive to MMC than XPA cells (Fig. 2.9 C).
We hypothesize that the relative amount of ICLs compared with the total amount of DNA
damage may impact this differential phenotype with ERCC1 deficiency. To assess
differences in ICL-R between our isogenic cell lines, we performed modified alkaline
comet assays in the H522 and H1299 isogenic cell lines. Although this assay is an
indirect measure of interstrand crosslinked DNA, it is commonly used to measure
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Figure 2.9 Sensitivity of XPA knockout cells to cisplatin and mitomycin C. A.
Western blot validation of XPA knockout by CRISPR-Cas9. Colony survival assay of
H1299 WT, ERCC1, XPF, and XPA after B. cisplatin and C. MMC treatment. D.
Validation of second XPA clone by western blot. E. Colony survival assay of H1299 WT
and second XPA clone with cisplatin treatment.
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platinum ICL-R. H1299 cells were treated with 5 mol/L and H522 cells with 1.5 mol/L
cisplatin for two hours followed by measurements of ICL-R at the 0- (immediately after
treatment), 24-, and 48-hour timepoints. Despite attempts to perform these analyses with
H460 isogenic cell lines, the ERCC1 cells were too sensitive to cisplatin to observe
significant differences between untreated and treated samples at the 0-hour time point
when treated with 500 nmol/L cisplatin, making it impossible to accurately monitor ICL
DNA repair via this assay. As we expected, H522 ERCC1 cells were not capable of
ICL-R (Fig. 2.8 C). In H522 ERCC1/p53* cells, ICL-R was at least partially rescued
where there was no difference compared with WT or p53* cells at the 24-hour time point,
but statistically greater amounts of ICL DNA damage remained at 48 hours
posttreatment relative to p53* cells and less amounts of damage remained relative to
ERCC1 cells (Fig. 2.8 C). This observation would be consistent with partial disruption
of TP53 in these cells. Consistent with the DNA damage signaling we observed in
H1299 ERCC1 cells, no delay in ICL-R compared with H1299 WT cells was detectable
(Fig. 2.8 C), however, re-expression of p53 in H1299 ERCC1 cells induced a nearcomplete block of ICL-R compared with parental cells (Fig. 2.8 C).
2.3.4 Cell-cycle arrest profiles differ in ERCC1 cells after cisplatin treatment
Many reports with ERCC1 knockout and knockdown cells have shown that after
treatment with a crosslinking agent there is a potent G 2–M cell-cycle arrest which has
been attributed to unrepaired DNA damage. To test whether p53 status affected cellcycle arrest after treatment with cisplatin, we assessed cell-cycle profiles in a time
course after treatment. Although the p53 null H1299 cells exhibited no distinct G 2–M
arrest after platinum treatment, we consistently observed a slight increase in G 2–M
arrest in the H1299 ERCC1 cells at the 24-hour time point, which resolved by the 48-
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Figure 2.10 Cell-cycle profiles after cisplatin treatment in ERCC1 isogenic cell
lines. Representative data from flow cytometry experiments measuring cell cycle profiles
in A. H1299 and B. H460 isogenic cells at varying time points after cisplatin treatment (n
= 2 for each sample). C. Quantification of the percent of cells in G2–M phase following
cisplatin treatment. Analysis excludes the sub-G1 population of cells from the
quantification.
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hour time point (Fig. 2.10 A and C). Conversely, in H460 ERCC1 cells, we observed a
potent G2–M arrest 24 hours post-cisplatin treatment (Fig. 2.10 B and C). By 48 hours
post-treatment, we detected a sharp increase in a sub-G1 population consistent with an
increase in cell death. In the H460 ERCC1/p53* cells, we observed the same potent
G2–M arrest that we observed in H460 ERCC1 cells at 24 hours post-treatment (Fig.
2.10 B and C). Astonishingly, by 72 hours after treatment, we saw a near-complete
recovery from G2–M arrest with only a minor increase in the sub-G1 population. We
hypothesize that unrepaired DNA damage leads to G2–M arrest but that this G2–M arrest
is not permanent. Eventually cells enter into M-phase and subsequently into G1 phase
where the presence of DNA DSBs triggers p53-mediated cell death. However, in the
absence of p53, cells are either capable of tolerating unrepaired DNA crosslink damage
or alternate repair mechanisms may exist that can at least partially compensate for loss
of ERCC1.
2.3.5 p53 status may act as a confounding variable in clinical assessments of
ERCC1 as a platinum biomarker
The potential for utilizing ERCC1 expression to predict clinical response to
platinum-based chemotherapy has been extensively tested in multiple cancer types
including lung and ovarian cancers with varying results (13, 163, 185, 186). We wanted
to assess whether p53 status may be a confounding variable. Utilizing the TCGA lung
adenocarcinoma data set, we split patients into two groups; those whose tumors had WT
TP53 and those whose tumors had any amino acid-changing mutation in TP53. Although
we did not observe any significant difference in ERCC1 expression between groups (p =
0.156), when we stratified WT p53 tumors based upon ERCC1 high or low expression,
we observed a significant 50% increase in median OS for patients with low ERCC1 (Fig.
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Figure 2.11 ERCC1 expression and p53 status in relation to OS in the TCGA lung
adenocarcinoma data set. A. Expression of ERCC1 in lung adenocarcinoma tumors
delineated by p53 status. Data compared by Student t test. OS of lung adenocarcinoma
patients whose tumor harbored B. WT p53 and stratified by ERCC1 expression, or C.
mutated p53 and stratified by ERCC1 expression. D. Combined model of OS of patients
with lung adenocarcinoma accounting for p53 status and ERCC1 expression.
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Figure 2.12 ERCC1 expression and p53 status in relation to OS in ovarian serous
cystadenocarcinoma. Top: Progression Free Survival of Stage 3+4 ovarian cancer
patients stratified by p53 status and ERCC1 expression who received a platinum agent.
Bottom: Overall Survival of Stage 3+4 ovarian cancer patients stratified by p53 status
and ERCC1 expression who received a platinum agent. Data obtained from the 2017
TCGA Ovarian Cancer Data Set from kmplot.com/ovca.
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2.11 A, B, and D). However, in patients whose tumors had p53 mutations, no significant
increase in median OS for patients with low compared with those with high ERCC1 was
observed (Fig. 2.11 C and D). Although TCGA lung adenocarcinoma treatment data are
not publicly available, nearly 100% of patients with lung adenocarcinoma receive a
platinum agent during the course of treatment, and so we hypothesize that these data
are contingent upon platinum treatment. We also corroborated these results in the TCGA
ovarian cancer data set in terms of both progression-free and OS specifically in the
context of platinum treatment (Fig. 2.12).
We also tested whether ERCC1 expression predicted OS in terms of response to
platinum-based chemotherapy depending upon KRAS status (a common driver gene in
non-small cell lung cancer) as there was a recent observation that KRAS status
predicted platinum response in pancreatic cancer (187). KRAS status itself was not
predictive in our TCGA lung adenocarcinoma data set (p = 0.46). Importantly, KRAS
mutations were found to be mutually exclusive with TP53 mutations (p < 0.001),
demonstrating that in most cases KRAS mutations occur in TP53 wildtype specimens
and vice versa TP53 mutations occur in KRAS wildtype specimens. In ovarian serous
cystadenocarcinoma TP53 mutations and KRAS mutations also had a tendency toward
mutual exclusivity (p = 0.184) but a detailed study on this would need additional
statistical power considering TP53 mutations in ovarian cystadenocarcinoma occur in
approximately 90% of tumors. These observations are directly opposed to pancreatic
adenocarcinoma, where KRAS and TP53 mutations significantly co-occur (TCGA and
QCMG; p < 0.001). This constitutes a major difference between these tumor types and
has direct implications for our study assessing ERCC1 expression and TP53 mutational
status in lung adenocarcinoma and ovarian cystadenocarcinoma. ERCC1 did retain its
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observed effects on prognosis when accounting for KRAS mutation status in the TCGA
cohort (p = 0.0008). We observed a significant difference in survival in terms of ERCC1
expression in the KRAS mutant group, which happens to be overwhelmingly TP53
wildtype. Thus, the KRAS and ERCC1 analysis is confounded by TP53 status. Due to
the mutual exclusivity of TP53 mutations and KRAS mutations, stratification of the KRAS
sample into ERCC1 high/low and TP53 mutant and wildtype was not feasible with
adequate statistical power. This data suggests that to investigate the effects of ERCC1
and TP53 mutation status in the context of KRAS mutations at the population level, a
separate study would need to target a substantial enrollment of KRAS mutant cancers
due to the relative rarity of TP53 mutations in these specific cancers. Additionally, we did
not specifically test the effects of including BRCA1/2 mutation status in our analysis;
however, BRCA1/2 mutations are generally observed in a p53 mutant context where we
did not observe a significant benefit for patients with low ERCC1 in the context of OS.
2.3.6 Mechanistic characterization of ICL tolerance with ERCC1-deficiency
We hypothesized that in a p53 mutant/null background where apoptosis and G1
checkpoint activation are diminished, alternate repair mechanisms may exist to deal with
the damage from unrepaired ICLs that accumulate as result of loss of ERCC1. It is well
documented that ERCC1/XPF activity is critical for ICL-R in G1 phase, where replicationdependent processes are not available for dealing with ICLs, so we tested whether
transient inhibition of entry into S phase could sensitize ICL-tolerant ERCC1 cells to
cisplatin. Palbociclib alone inhibited growth of H1299 WT and ERCC1 cells and
corresponded with an increase in the percentage of cells in G1 phase compared with
untreated cells (Fig. 2.14 C and D). For combination treatment experiments, we treated
cells with cisplatin followed by 24-hour treatment with the CDK4/6 inhibitors, palbociclib
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Figure 2.13 Molecular pathways contributing to cisplatin tolerance in p53-null cells with
ERCC1 deficiency. A. Clonogenic survival assays of H1299 WT and ERCC1 cells
treated with cisplatin and palbociclib, ribociclib, or DBF4-dependent kinase inhibitor. Left:
Plot depicts one representative experiment (n = 3). Middle: Plot represents average of 3
independent experiments. Right: Plot represents 1 representative experiment (n = 3). B.
Clonogenic survival of H1299 isogenic cells treated with cisplatin ± NU7441 (DNA-PKcs
inhibitor; n = 3). C. Western blot analysis showing BRCA1 knockdown and clonogenic
assays of H1299 WT and ERCC1 with shControl and shBRCA1 knockdown. D.
Quantification of H2AX foci formation 48 hours post-cisplatin treatment in H1299 WT
and ERCC1 BRCA1 knockdown cells ± cisplatin treatment. Data are representative of
2 independent experiments. ****, P < 0.0001 as measured by Wilcoxon rank-sum test.

73

and ribociclib. We observed that H1299 WT and ERCC1 cells could be sensitized to
cisplatin in clonogenic assays even with transient inhibition of CDK4/6 activity (Fig. 2.13
A; Fig. 2.14 B), which was very similar to what we observed with re-expression of p53
(Fig. 2.6 A). The addition of palbociclib to hypersensitive H460 or H522 ERCC1 cells
did not further enhance cisplatin sensitivity, although there were small increases in
sensitivity for the parental cell lines (Fig. 2.14 A and B). Furthermore, blocking replication
initiation in H1299 ERCC1 cells via inhibiting the DBF4-dependent kinase (DDK) with
the inhibitor, XL413, could also sensitize to cisplatin (Fig. 2.13 A). We take this to
suggest that in hypersensitive ERCC1 cells, ICL-R is completely dependent upon
ERCC1/XPF activity whether or not cells are in G1 or S–G2–M phases of the cell cycle.
However, the increased sensitivity of H1299, H460, and H522 WT cells with CDK4/6 or
DDK inhibition may indicate that timely entry into S-phase is also critical for supporting
platinum resistance despite being DNA repair proficient. This requirement for S-phase
entry appears to be exacerbated in p53-null H1299 ERCC1 cells where platinum
sensitization by CDK4/6 or DDK inhibition indicates that ERCC1/XPF activity is critical
for ICL-R in G1 phase in ICL-tolerant cells, and that entry into S-phase may lead to
ERCC1/XPF-independent mechanisms for tolerating or repairing ICL-DNA damage.
Next, we tested whether factors involved in nonhomologous end joining (NHEJ) and HR
supported the tolerance observed in H1299 ERCC1 cells. Inhibition of DNA-PKcs
activity with the inhibitor, NU7441, selectively increased sensitivity of ERCC1 H1299
cells (1.3 mol/L vs. 0.5 mol/L), but not parental cells, to cisplatin (Fig. 2.13 B). In
addition, we performed shRNA knockdown of BRCA1 in H1299 cells and assessed
clonogenicity after cisplatin treatment. BRCA1 knockdown led to increased sensitivity in
both H1299 WT and ERCC1 cells, consistent with critical roles for BRCA1 in regulating
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Figure 2.14 Sensitivity of ERCC1 knockout/p53 wildtype cells to CDK4/6 inhibition
and effects of BRCA2 knockdown on H1299 sensitivity to cisplatin. A. Treatment of
H460 and H522 cells with palbociclib in clonogenic survival assays. n=3, plated in
triplicate for each cell line. Error bars represent ± SD. B. Effects of palbociclib treatment
on sensitivity to cisplatin in H460, H522, and H1299 WT and ERCC1 cell lines. C. Cell
cycle profiles of H1299 WT and ERCC1 cells with and without 48-hour treatment with
palbociclib (representative from 2 independent experiments). D. Relative cell number of
untreated and palbociclib treated H1299 WT and ERCC1 cells. E. Cell Titer Glo Assay
with shControl and shBRCA2 H1299 WT and ERCC1 cells and transcript expression
analysis via qRT-PCR showing knockdown of BRCA2 transcript levels. For all
clonogenic survival assays: n=3, plated in triplicate for each cell line. Error bars
represent ± SD.
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DSB end-resection and contributing to HR, translesion synthesis, and microhomologymediated end joining (Fig. 2.13 C). Interestingly, the effects of BRCA1 knockdown in
sensitizing ICL-tolerant ERCC1 cells to cisplatin appear to be independent of BRCA2
as we only observed increased sensitivity in WT cells, but no increased sensitivity of
ERCC1 cells to cisplatin (Fig. 2.14 E). Furthermore, BRCA1 knockdown led to a
significant increase in the presence of H2AX foci persisting 48 hours post-cisplatin
treatment in the H1299 ERCC1 cells treated with cisplatin compared with ERCC1
alone (Fig. 2.13 D). Although the mechanism underlying ICL-tolerance in a subset of
ERCC1 cells is not entirely parsed out, it appears that this tolerance is dependent upon
DNA-PKcs and BRCA1 function, but likely independent of BRCA2.
2.4 Discussion
A recent international randomized phase III clinical trial utilizing ERCC1
expression to predict response to platinum-based chemotherapy did not show clinical
benefit for patients with non–small cell lung cancer with low ERCC1 who received a
platinum agent (163, 185). In addition, a preclinical study failed to show any correlation
between pretreatment ERCC1 expression in ovarian cancers and response to platinumbased chemotherapy (186). Here, we showed that our in vitro data may have direct
clinical implications where we observed a clinical benefit for patients with lung
adenocarcinoma and ovarian carcinoma with low ERCC1 only when WT p53 was
retained. These data may provide an additional explanation for conflicting results from
clinical studies as to the benefit of using ERCC1 expression to predict responders to
platinum-based chemotherapy. Our data may have the greatest impact in cancer types
where the p53 mutation rate is markedly high, such as lung adenocarcinoma (50% p53
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mutant) and ovarian serous carcinoma (90%), where ERCC1 has been investigated as a
platinum biomarker.
In this study, we characterized a panel of ERCC1 lung cancer cell lines. We
identified a differentially sensitive phenotype of ERCC1 lung cancer cell lines that
appears to be at least partially associated with p53 status. If cells harbored WT p53, the
ERCC1 deletion clones exhibited hypersensitivity to crosslinking agents, whereas the
p53mutant/null cell lines exhibited mild sensitivity. Viability after cisplatin treatment of
ERCC1 cells was dramatically increased by disrupting p53 by CRISPR-Cas9.
However, clonogenicity of ERCC1 cells increased by disrupting p53 whereas sensitivity
was increased in ERCC1/p53null cells following expression of TP53 cDNA. The modest
increases in clonogenicity in isogenic ERCC1 cells with subsequent disruption of p53
compared with our panel of ERCC1 cells likely suggests additional factors, such as
those involved in processing and stability of replication forks (RPA availability for
example), may be critical for further enhancing clonogenicity in response to platinums
with loss of ERCC1 (188). This would be most significant in terms of factors involved in
response to intrastrand DNA damage which also theoretically requires ERCC1/XPF
activity for resolution. A similar phenotype was observed by Feng and Jasin, where they
observed a similar partial, but significant, rescue of clonogenicity of BRCA2-deficient
cells with p53 loss, potentially suggesting that alterations in additional factors or
pathways are critical for supporting clonogenic growth in tumors harboring a p53
mutation and loss of BRCA2 (189).
Interestingly, modified alkaline comet assays in H522 and H1299 cell lines
showed differential repair of ICLs depending on p53 status. We also demonstrated that
ERCC1 cells exhibit G2–M arrest following cisplatin treatment. p53 disruption in H460
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ERCC1 cells did not alter the initial G2–M arrest observed in H460 ERCC1 cells,
however, at 48 hours posttreatment there was a dramatic increase in a sub-G1
population in H460 ERCC1 cells that corresponded with a decrease in the G2–M
population. This is opposed to the near complete abrogation of cell death and G2–M
arrest in the H460 ERCC1/p53* cells.
Of importance, transient inhibition of entry into S-phase sensitized ICL-tolerant
ERCC1/p53* cells to cisplatin, suggesting ERCC1/XPF is indeed critical for ICL-R in G1
phase and that the persistence of these unrepaired ICLs may trigger growth inhibition.
This growth inhibition also suggests that entry into S-phase is critical for supporting ICL
tolerance in these cells where there may be decreased dependence on ERCC1/XPF for
ICL unhooking resulting in the accumulation of DNA DSBs. Based upon our data, it is
likely that loss of downstream functions of ERCC1/XPF in ICL-R lead to persistent DSBs
that are unresolved, at least initially, leading to G2–M arrest. However, cells eventually
escape this arrest and enter into M and subsequently into G1 phase where p53 activity is
critical for sensing persistent DNA damage from the previous round of the cell cycle and
triggering apoptosis as well as activating the G1 checkpoint. It is most likely that loss of
p53 leads to a decrease in this apoptotic potential and loss of G1 checkpoint activation
which enables secondary, alternate repair pathways to at least partially contribute to
ICL-R either in later stages of the cell cycle or in the subsequent G1 phase where a
number of error-prone repair pathways, independent of BRCA2, may be available,
including break-induced replication, microhomology-mediated end joining, and NHEJ.
This hypothesis is supported by the observation that DNA-PKcs and BRCA1, but not
BRCA2, are critical for supporting tolerance to ICLs in the absence of p53 and ERCC1.
A similar phenotype with BRCA1 was recently reported in MMC-resistant, FANCC-
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deficient cells where BRCA1 function was critical for supporting MMC resistance in the
absence of USP48, despite loss of canonical ICL-R (172). Together, these data suggest
that in both p53 and ICL-R deficient cells there is the potential uncovering of alternate
DNA repair or tolerance mechanisms for dealing with unrepaired ICLs that specifically
relies upon DNA-PKcs and BRCA1 as well as entry into S phase.
Several other groups have identified similar differential phenotypes in vitro and in
vivo with loss of factors involved in ICL-R that appear to be correlated with p53 status
including Mus81, BRCA2, and FANCD2 (171, 189, 190), although a mechanism for this
differential phenotype has not been described. However, the role of p53 in inducing
apoptosis does not appear to fully account for this differential phenotype as a recent
report showed in FANCD2-deficient mice that p53 loss completely rescued mice from FA
symptoms specifically in the context of aldehyde-DNA ICLs (171). Although the
abrogation of FA symptoms was certainly related to a reduction in apoptosis, the authors
also observed a dramatic increase in chromosomal aberrations including deletions and
translocations suggesting that loss of p53 may uncover an alternate, error-prone ICL-R
pathway and that WT p53 serves to suppress this error-prone repair likely through its
roles in controlling apoptosis and mediating cell-cycle control. In conclusion, the work in
this study characterizes a novel phenotype of ICL-tolerance in a subset of ERCC1deficient cells and highlights the potential importance of p53 as a clinically relevant
variable in studies evaluating ERCC1, and possibly other ICL-R factors, as a platinum
biomarker. The surprising finding that DNA-PKcs and BRCA1 support this phenotype of
tolerance suggests there are repair mechanisms in place which can at least partially
overcome the ICL-R defects associated with loss of ERCC1. Furthermore, it will be
important to fully characterize the molecular mechanisms underlying this process and to
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expand the list of repair factors that are involved in supporting resistance to crosslinking
agents despite loss of canonical ICL-R.
Better understanding mechanisms of resistance to DNA crosslinking agents in
the context of DNA repair deficiencies may lead to the identification of novel targets for
therapeutic intervention that could be developed to improve patient responses to
platinum-based chemotherapy.
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CHAPTER 3- ATR SUPPORTS PLATINUM TOLERANCE WITH ERCC1 DEFICIENCY
BY SUPPRESSING REPLICATION CATASTROPHE

3.1 Introduction
DNA crosslinking agents, including the platinum-based analogues remain
mainstay treatments for a variety of neoplasms. These crosslinking agents function by
covalently binding to guanines in the DNA thereby blocking DNA replication and
inhibiting tumor cell growth. These agents form a variety of DNA lesions including
monoadducts, intrastrand crosslinks (ISAs), and interstrand crosslinks (ICLs) which
ultimately require different pathways for ultimate resolution of the DNA damage including
Nucleotide Excision Repair (NER), Homologous Recombination Repair (HR), and
Interstrand Crosslink Repair (ICL-R).
Perhaps no DNA repair factor, excluding BRCA1 and BRCA2, has had more
clinical interest in terms of biomarkers for response to cancer therapy than the NER
factor, ERCC1 (13, 123, 154, 163). ERCC1 forms a constitutive heterodimer with the
protein XPF which together constitutes a 5’-3’ structure-specific endonuclease.
ERCC1/XPF has critical roles in multiple DNA repair pathways including NER, ICL-R,
HR and single strand annealing. In general, it is believed that ERCC1/XPF nuclease
activity is essential for repair of platinum-induced DNA damage. ERCC1 was first
identified as a potential biomarker for predicting response to platinum-based
chemotherapy in the late 1990s and early 2000s and up to 60% of lung
adenocarcinomas and up to 30% of lung squamous cell carcinomas harbor low to
undetectable ERCC1 expression at the mRNA and protein levels (139, 151, 153, 191).
However, the clinical utility of ERCC1 expression has been hampered by problems with
antibody specificity, splice variant expression and inconsistent results in retrospective
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clinical studies (13). Furthermore, a recent clinical trial in non-small cell lung cancer
failed to show a survival benefit for patients with low ERCC1 who received a platinum
agent (163, 185). Together, these observations suggest there remains an incomplete
understanding of the biology of ERCC1 in human tumors.
Work from our lab recently identified a synthetic viable interaction between
ERCC1 loss and p53 loss in a panel of ERCC1 knockout cell lines that we could
recapitulate in two separate patient data sets (30). We observed that ERCC1-deficient
cell lines harboring a mutation in or that were null for p53 were tolerant to crosslinking
agents including cisplatin and mitomycin C (MMC) and that this tolerance was supported
by DNA-PKcs and BRCA1 function as well as timely entry into S-phase following DNA
damage (30). We hypothesized that p53 was critical for sensing persistent, replicationassociated DNA damage in the subsequent G1 phase in platinum-treated ERCC1
knockout cells and that this function of p53 is what accounted for differential phenotypes
in response to DNA crosslinking agents with loss of ERCC1. However, when we deleted
wildtype p53 from hypersensitive ERCC1 knockout cells, we could nearly completely
rescue viability after platinum treatment, but only mildly increase clonogenicity (30). This
led us to hypothesize that functional loss of p53 may be necessary but insufficient to
completely account for the differences in sensitivity between ERCC1 knockout cell lines
and that additional processes during replication (e.g. RPA bioavailability) may be critical
for promoting clonogenicity after platinum treatment with loss of ERCC1 by suppressing
the accumulation of replication-associated DNA damage (188).
In the current study, we build upon our recent work identifying a novel subset of
platinum-tolerant, ERCC1-deficient lung tumors by exploring the possibility of utilizing
the ATR inhibitor M6620 as a means of overcoming platinum tolerance with ERCC1
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deficiency. Utilizing previously established ERCC1 knockout cell line models of
hypersensitivity and tolerance to DNA crosslinking agents, we show that synthetic
lethality between ERCC1 loss and ATR inhibition depends upon cells being
hypersensitive to crosslinking agents. These data potentially link the tolerance to DNA
crosslinking agents in an ERCC1-deficient background to increased replication fork
stability. On the other hand, we observe that tolerance to platinum and MMC with
ERCC1 loss completely depends upon ATR function. Conversely, in an ERCC1
knockout cell line that is de facto hypersensitive to DNA crosslinking agents (i.e. ERCC1
knockout/p53 wildtype), there is no enhanced sensitivity to these agents with addition of
an ATR inhibitor suggesting that even in the presence of ATR activity, there may be
reduced capacity for fork protection in these cells. Treating platinum tolerant, ERCC1
knockout cells (i.e. ERCC1 knockout/p53 null) with platinum did not dramatically lead to
increases in DNA double strand breaks following treatment. However, the addition of an
ATR inhibitor promoted substantial increases in DNA double strand breaks following
treatment. Finally, these increases in DNA double strand breaks were associated with
substantial increases in replication catastrophe and subsequent micronuclei formation.
Thus, in platinum tolerant, ERCC1 knockout cells, ATR promotes tolerance to DNA
crosslinking agents by preventing the accumulation of aberrant DNA breaks and
suppressing replication catastrophe. This work demonstrates the importance of ATR
activity to promote tolerance to platinum-based chemotherapy in ERCC1 deficient cells
and shows that chemical inhibition of ATR kinase activity by M6620 may represent a
viable strategy for overcoming platinum tolerance in ERCC1 deficient tumors harboring a
mutation in p53.
3.2 Materials and Methods
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3.2.1 Cell Lines and Cell Culture
H460 and H1299 lung cancer cell lines were obtained from ATCC and were
authenticated by the Karmanos Cancer Institute Biobanking and Correlative Sciences
Core Facility. Cell lines were maintained in RPMI-1640 medium (Dharmacon)
supplemented

with

10%

Fetal

Bovine

Serum

(Atlanta

Biologicals)

and

1%

Penicillin/Streptomycin (Dharmacon) and cells were grown in a humidified incubator with
5% CO2. Cell lines were utilized for experiments for no greater than ~25 passages.
ERCC1 and TP53 knockout cell lines have been previously validated and published (30,
135).
3.2.2 Western Blot
100 g protein was loaded onto 10% Mini-PROTEAN TGX precast gels (BioRad; 456-1043) and run at 150 V for ~40 minutes in Tris/Glycine/SDS buffer (Bio-Rad;
1610732). Proteins were transferred onto PVDF membrane at 100 V for ~35 minutes in
transfer buffer (10 mmol/L CAPS, 10% Methanol, pH 10.5). Membrane was blocked for
one hour with 5% non-fat milk in TBS-Tween. Proteins were probed overnight at 4 oC
with anti-ERCC1 (Abcam; ab76236; 1:1,000), anti-XPF (Santa Cruz; sc-136153;
1:1,000), or for one hour at room temperature with anti--actin (Sigma-Aldrich; A5441;
1:100,000) in antibody dilution buffer (3% w/v bovine serum albumin (BSA), 0.2% v/v
sodium azide in PBS-Tween). Excess antibody was removed by washing three times
with PBS-Tween and the membrane was subsequently probed with goat anti-mouse or
goat anti-rabbit secondary antibodies (Bio-Rad; 172-1011 and 172-1019; 1:2,000) for 45
minutes at room temperature. Excess secondary antibody was removed by washing
three times with PBS-Tween.
3.2.3 Colony Survival Assay
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Clonogenic survival assays were performed essentially as previously described
(30). The day prior to treatment, 300 – 500 cells were seeded in complete medium in 60
mm plates. The day following seeding, cells were treated for varying times depending on
the drug utilized in serum-free medium. Cisplatin (Sigma-Aldrich; 479306) was prepared
daily as a fresh 1 mmol/L stock in PBS. All cisplatin treatments in clonogenic assays
were performed for two hours. M6620 (Selleckchem; S7102), MK-1775 (Selleckchem;
S1525), BMN 673 (Selleckchem; S7048), KU-55933 (Selleckchem; S1092) and CHIR124 (Selleckchem; S2683) were prepared in DMSO, and treatments were performed for
four hours. Mitomycin C (Selleckchem; S8146) was prepared in DMSO and treatments
were performed for two hours. Once colonies reached a size of at least 50 or more cells,
plates were washed once with PBS, and crystal violet was added (20% ethanol, 1% w/v
crystal violet). For synergy studies, a constant cisplatin:M6620 ratio was utilized that was
based upon the approximate IC50 value for each drug in each cell line (for H460
ERCC1 cells a ratio of 1:4 cisplatin:M6620 and for H1299 ERCC1 cells a ratio of 4:3
cisplatin:M6620 was used). Colony assay data were plotted and IC50s estimated using
Sigma Plot version 10.0.
3.2.4 Immunofluorescence
Cells were treated with the indicated concentrations of cisplatin (two hours),
M6620 (four hours) or combination. For H2AX foci experiments in Figure 4A, 10 mol/L
CDK1 inhibitor (RO-3306; Selleckchem; S7747) was added. For experiments presented
in Figure 4A, immunofluorescence was performed ~16 hours after treatment. For
experiments

presented

in

Figure

5,

no

CDK1

inhibitor

was

added

and

immunofluorescence was performed ~40 hours after treatment. Cells were fixed with 4%
paraformaldehyde for 20 minutes at room temperature, washed once with wash buffer
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(0.1% Triton-X 100 in PBS), followed by permeabilization with 0.3% Triton-X 100 in PBS
for 15 minutes. For micronuclei experiments, cells were stained with DAPI and
coverslips sealed with nail polish. Cells were washed twice with wash buffer in PBS and
blocked for one hour at room temperature using blocking buffer (0.02% Tween 20, 5%
BSA in PBS). Cells were incubated with primary antibody (cGAS; Cell Signaling;
D1D3G; 1:500 and/or H2AX-S139; EMD Millipore; JBW301; 1:1000) for 90 minutes at
room temperature. Coverslips were washed with wash buffer and secondary antibody
was added for one hour at room temperature in the dark (Alexa Fluor 488 goat antimouse IgG (H+L); Life Technologies; A11029; 1:2000 and Alexa Fluor 568 goat antirabbit IgG (H+L); Life Technologies; A11011; 1:1200). Coverslips were washed with
wash buffer and with a final rinse with PBS. Cells were incubated with ProLong Gold
antifade reagent with DAPI (Life Technologies; P36931) and coverslips were sealed with
nail polish. Images were taken with a Nikon epifluorescent microscope using a 40x air
objective. Micronuclei were quantified by visual inspection. Images were equally
adjusted for presentation purposes.
3.2.5 Metaphase Spreads
For experiments utilizing chronic exposure to low dose cisplatin and M6620, cells
were treated with 100 nmol/L cisplatin, 100 nmol/L M6620, or 100 nmol/L cisplatin + 100
nmol/L M6620 in complete medium daily for two days. For experiments utilizing a single
concentration of cisplatin and M6620, cells were treated with 500 nmol/L cisplatin for two
hours, followed by pulse labeling with 10 µmol/L EdU for 15 minutes, and subsequently
treated with 750 nmol/L M6620 for four hours. 48 hours after chronic or single dose
treatment, cells were incubated with Karyomax Colcemid (Life Technologies; 15212012)
at 0.2 µg/mL for 90 minutes. Cells were subsequently suspended in ice cold 0.56% KCl
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for 15 minutes at room temperature. Next, cells were fixed on ice in 3:1 methanol:acetic
acid for approximately one hour. ~20 µL was added dropwise onto slides and allowed to
air dry for 30 minutes followed by brief heat fixation. For EdU-incubated samples, slides
were rehydrated with 3% BSA in PBS, followed by a 30-minute click chemistry reaction
using an AF488 EdU Click It kit (Thermo Fisher; C10337). DNA was stained with antifade solution containing DAPI, a coverslip was added, and slides were sealed with nail
polish. Spreads were counted on a Nikon epifluorescent microscope using a 40x oil
objective. Images presented in this manuscript were taken on a Zeiss LSM 780 confocal
microscope using a 63x oil objective. Images were cropped and entire images were
equally sharpened or contrast adjusted for presentation purposes. For quantification of
spreads, 50 or more spreads were counted for each condition. Experiments were
performed three times.
3.2.6 Flow Cytometry
Cell Cycle: 5 x 105 cells were seeded on 10 cm plates. The following day, cells
were incubated with 2 mmol/L thymidine overnight. Thymidine was removed and cells
were allowed to grow for 8 hours followed by the addition of 2 mmol/L thymidine. For
treatment, cells were treated with 1 mol/L cisplatin in the presence of thymidine for two
hours, and then released from the thymidine block into complete medium containing
either no drug or 1 mol/L M6620 for four hours. Samples were collected for Flow
cytometry at the 4-hour, 22-hour, and 46-hour timepoints. Cells were fixed in 66%
ethanol and stored at 4 oC for no greater than four days. Cells were prepared for
detection of DNA content by flow cytometry using PI/RNase Staining Buffer (BD
Biosciences; 550825) as per the manufacturer’s instructions (with the exception that all
spin steps were performed at 1,000 rpm for 3 minutes). Flow cytometry was performed
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on a BD LSR II SORP Flow Cytometer (BD Biosciences). Data were analyzed using
ModFit LT (Verity Software House) and FlowJo v10 (FlowJo, LLC). Apoptosis: On the
day prior to treatment, cells were seeded onto 10 cm plates. Cells were treated with
either 1 mol/L cisplatin (two hours), 1 mol/L M6620 (four hours) or combination. ~48
hours post-treatment, cells were processed for detection of 7-AAD and PE Annexin-V
staining using the PE Annexin V Apoptosis Detection Kit I (BD Biosciences; 559763) as
per the manufacturer’s instructions. Flow cytometry was performed on a BD LSR II
SORP Flow Cytometer (BD Biosciences). Data were analyzed using FlowJo v10
(FlowJo, LLC).
3.2.7 Senescence Assays
Cells were seeded in 6 well plates on the day prior to treatment. Cells were
subsequently left untreated, treated with 500 nmol/L cisplatin for 2 hours, 500 nmol/L
M6620 for 4 hours, or 500 nmol/L cisplatin + 500 nmol/L M6620. Cells were allowed to
grow for six days after which cells were fixed and subsequently incubated with X-gal
substrate overnight at 37

C as per the manufacturer’s instructions using a β-

o

galactosidase staining kit (Cell Signaling Technologies). Experiments were performed
twice, and images taken on a Nikon epifluorescent microscope using a 20x air objective.
Images were equally adjusted for presentation purposes.
3.2.8 Statistical Analyses for Cell Line Studies
All experiments were performed three times with the exception of flow cytometry
and beta-galactosidase staining which were performed two times. IC50 values of drug
sensitivity were estimated using Sigma Plot (v.10.0) from three independent experiments
and values compared by two-sample t test. For comparisons of plating efficiency,
normalized values were quantified from three independent experiments and compared
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by two-sample t test. For metaphase spread experiments, data were compared by twosample t test.
3.2.9 TCGA Analysis
Data were analyzed using cbioportal.org. Utilizing each data set indicated in
Figure 3.2, mRNA expression (RNA Seq V2 RSEM) was compared between ERCC1
and ATR and ERCC1 and Chek1.
3.3 Results
3.3.1 Differential response of ERCC1 cell lines to cisplatin, mitomycin C, and ATR
inhibition
We previously established a panel of ERCC1 knockout lung cancer cell lines and
observed a differential phenotype in terms of response to cisplatin and MMC (30). We
observed hypersensitivity to DNA crosslinks in ERCC1 deficient cells only when wildtype
p53 was retained while those cell lines that were null for or harbored a mutation in p53
were significantly more tolerant to DNA crosslinks despite complete loss of ERCC1
(Figure 3.1 A). This led to the identification of two subsets of ERCC1-deficient tumors:
platinum-hypersensitive and platinum-tolerant (Figure 3.1 A). Since our previous work
identified DNA-PKcs, BRCA1, and timely progression into S-phase as being critical
regulators of platinum-tolerance with ERCC1 deficiency, we focused our efforts on
understanding whether inhibition of the DNA damage kinase, ATR, by the potent and
highly selective small molecular inhibitor, M6620, could selectively sensitize platinumtolerant, ERCC1-deficient cells and tumors to platinum-based chemotherapy. We utilized
previously established lung cancer models of ERCC1-deficiency for our current studies,
including the platinum hypersensitive model, H460, and the platinum-tolerant model,
H1299 (Figure 3.1 A and 1B). We confirmed our previously reported observations of a

89

differential sensitivity to the DNA crosslinking agents, cisplatin and MMC, in our ERCC1deficient cell line models. A clear hypersensitivity to cisplatin and MMC was observed in
H460 ERCC1 knockout cells while the platinum-tolerant, ERCC1-deficient H1299 model
was not dramatically more sensitive to cisplatin or MMC compared to H460 and H1299
ERCC1-wildtype cells (Figure 3.1 C and D).
There are mixed reports that ATR inhibition is synthetic lethal with loss of
ERCC1, so we tested whether there were differences in response to the ATR inhibitor,
M6620 and the Chk1 inhibitor, CHIR-124, between our platinum-hypersensitive and
platinum-tolerant ERCC1 knockout cell line models (192-194). We observed that the
platinum-hypersensitive H460 ERCC1 knockout cells were also sensitive to both ATR
and Chk1 inhibition, however there was no synthetic lethality with ATR or Chk1 inhibition
in the H1299 ERCC1 knockout platinum-tolerant cells, suggesting that there are
compensatory processes occurring which not only render these cells tolerant to DNA
crosslinking agents, but also to inhibitors of the ATR pathway (Figure 3.1 E and F).
While there was a clear differential phenotype between ERCC1 knockout cell lines in
terms of sensitivity to ATR inhibition, the sensitization of H460 ERCC1 knockout cells to
Chk1 inhibition did not translate into a clear differential phenotype between H460 and
H1299 ERCC1 knockout cells (Figure 3.1 E and F).

Previous work looking at the

synthetic lethal relationship between ATR inhibition and ERCC1-deficiency proposed
that in the absence of ERCC1 there was increased reliance upon ATR-mediated
signaling to respond to increased levels of damage associated with loss of ERCC1/XPF
endonuclease activity (192). In support of this hypothesis, Mohni et al. identified
enrichment of ERCC1 at replication forks (192). Along these lines, we asked whether
there was any correlation between tumoral ERCC1 and ATR or Chek1 mRNA
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Figure 3.1 Differential sensitivity of ERCC1-knockout cells to cisplatin. A, Summary of
previously established cell line models of ERCC1 deficiency. B, Western blot depicting
ERCC1 and XPF expression in H460 and H1299 ERCC1 knockout cell lines. Sensitivity
of H460 and H1299 isogenic cell lines to C, cisplatin, D, mitomycin C, E, the ATR
inhibitor, M6620, and F, the Chk1 inhibitor, CHIR-124. All clonogenic assays are
presented as the average of three independent experiments ± standard deviation.
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Figure 3.2 Correlation between tumoral mRNA expression of ERCC1 and ATR or
Chek1 in multiple TCGA data sets. Accessed from cBIOportal.org.
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expression in tumors commonly treated with platinum-based chemotherapy. Utilizing
eight TCGA patient data sets of tumor types commonly treated with platinum-based
chemotherapy we observed moderate inverse correlations between tumoral ERCC1
mRNA and ATR mRNA suggesting that indeed ATR activity may be generally important
for compensating for loss of ERCC1 (Figure 3.2). Interestingly, no notable correlations
were observed between ERCC1 mRNA and Chk1 mRNA in the same data sets,
suggesting that either Chk1 expression may not be strongly controlled at the mRNA level
in the absence of ERCC1 or that Chk1 activity may not be as important as ATR for
compensating for loss of ERCC1 (Figure 3.2). Together these data may indicate that
certain compensatory mechanisms exist in platinum-tolerant, ERCC1 knockout cells to
deal with endogenous damage that accumulates as a result of loss of ERCC1.
3.3.2 ATR inhibition selectively sensitizes platinum-tolerant, ERCC1-deficient cells
to cisplatin
Because our previous work suggested that timely entry into S-phase was critical
for platinum-tolerance with loss of ERCC1, we tested whether ATR inhibition could
sensitize platinum tolerant, ERCC1-deficient cells to cisplatin. Utilizing a concentration of
the ATR inhibitor, M6620, that was toxic on its own, we observed a striking, significant
sensitization to cisplatin in H1299 ERCC1 knockout cells with ATR inhibition (1.50
mol/L vs. 0.19 mol/L) (Figure 3.3 A, C, & D). Conversely, in cells that were already
hypersensitive to cisplatin, the addition of an IC50 concentration of ATR inhibitor did not
further sensitize ERCC1-deficient cells to cisplatin (0.090 mol/L vs. 0.085 mol/L)
(Figure 3.3 B-D). Consistent with this observation upon cisplatin treatment, we saw a
similar pattern with MMC treatment, where ERCC1-deficient cells that were tolerant to
MMC could be sensitized by ATR inhibition without further enhancing MMC sensitivity in
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Figure 3.3 Platinum tolerance with ERCC1 deficiency is overcome by inhibition of ATR.
A, Sensitization of H1299 ERCC1 knockout cells to cisplatin by M6620 treatment. B,
Lack of sensitization of H460 ERCC1 knockout cells by M6620 treatment. C, Effect on
plating efficiency of H1299 and H460 ERCC1 knockout with the concentration of M6620
utilized in sensitization experiments. D, Table depicting IC50 values from sensitization
experiments depicted in Figure 2 A & B. IC50s were estimated using Sigma Plot software
and were compared by two-sided t test. E, Sensitization of H460 ERCC1 knockout/p53*
cells to cisplatin by M6620 treatment. F, Effect on plating efficiency of H460 ERCC1
knockout/p53* cells with the concentration of M6620 utilized in sensitization
experiments. G, Plots depicting synergy or lack of synergy between cisplatin and M6620
treatment in H460 and H1299 ERCC1 knockout cell lines. Data for all clonogenic assays
are presented as the average of three independent experiments ± standard deviation.
NS, not significant, * p<0.05, **** p<0.0001.
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Figure 3.4 Effects of ATR inhibition on sensitivity to mitomycin C in H460 and H1299
ERCC1 knockout cell lines. Clonogenic survival of A. H1299 or B. H460 ERCC1
knockout cells treated with mitomycin C or mitomycin C + M6620. C. Effect of
concentration of M6620 utilized for sensitization studies on plating efficiency relative to
untreated control. D. Table depicting IC50 values estimated utilizing Sigma Plot software
from experiments performed in A. and B. Data are presented as the average of three
independent experiments ± S.D. * p<0.05.
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ERCC1 knockout cells that were already hypersensitive (Figure 3.4 A-D). We previously
showed that knockout of p53 (p53*) in hypersensitive H460 ERCC1 knockout cells could
partially increase tolerance to cisplatin (30). Next, we asked whether H460 ERCC1
knockout/p53* cells could be re-sensitized to cisplatin by ATR inhibition. Indeed, we
observe that the increased tolerance to cisplatin in H460 ERCC1 knockout/p53* cells
could be overcome by ATR inhibition and H460 ERCC1 knockout/p53* cells were resensitized to same level as H460 ERCC1 knockout/p53WT cells (Figure 3.3 E and
F).These data show that the partial relationship between ERCC1 loss and p53 in terms
of platinum sensitivity may be related to levels of replication associated DNA damage
and ultimately ATR function in suppressing extensive replication fork collapse and
potentially replication catastrophe.

We then asked whether the enhanced cisplatin

sensitization we observed in H1299 ERCC1 knockout cells by ATR inhibition was
synergistic. Combination cisplatin and ATR inhibition was synergistic in H1299 ERCC1
knockout cells, while combination treatment was only additive in H460 ERCC1 knockout
cells (Figure 3.3 G). For this analysis, a point for combination treatment below the line
connecting the IC50 values for each drug represents a synergistic combination, while a
point on the line is an additive drug-drug interaction, and a point above the line is an
antagonistic drug-drug interaction.
As multiple protein targets have been studied in the context of sensitizing tumors
to platinum-based chemotherapy, we tested whether the effects of ATR inhibition were
independent of ATM inhibition. The addition of either 10 or 25 mol/L KU-55933 did not
enhance cisplatin sensitivity in H1299 ERCC1 knockout cells (Figure 3.5 A and B).
These data confirm that platinum-tolerance with ERCC1 relies specifically upon ATR
function and is not related to a more general inhibition of DNA damage kinase activity.
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Figure 3.5 Lack of sensitization of H1299 ERCC1 knockout cells to cisplatin by
ATM, PARP, Chk1, or Wee1 kinase inhibition. Clonogenic survival of H1299 ERCC1
knockout cells to cisplatin in combination with A. the ATM inhibitor KU-55933, C. the
PARP inhibitor, BMN-673, E. the Chk1 inhibitor, CHIR-124, and G. the Wee1 kinase
inhibitor, MK-1775. All results are presented as the average of three independent
experiments ± S.D. B, D, F, H. Concentrations of each drug utilized for sensitization
studies and the impact of each inhibitor on plating efficiency relative to untreated control.
n=3 ± S.D. ** p<0.01.
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Since PARP inhibitors have also entered clinical trials in combination with platinumbased chemotherapy, we asked whether ATR inhibition was a stronger sensitizer of
platinum-tolerant, ERCC1-deficient cells to cisplatin than the PARP inhibitor, BMN-673.
BMN-673 slightly enhanced sensitivity to cisplatin in H1299 ERCC1 knockout cells, but
this effect was mild and did not approach the level of sensitization induced by ATR
inhibition (Figure 3.5 C and D). Finally, we asked whether inhibiting the ATR target Chk1
or inhibiting the G2/M checkpoint kinase Wee1 could also sensitize H1299 ERCC1
knockout cells to cisplatin treatment. We observed no increased sensitivity to cisplatin in
H1299 ERCC1 knockout cells when we inhibited Chk1 or Wee1 kinase, suggesting that
the effects of ATR-mediated platinum sensitization in this specific context are likely
independent of Chk1- or Wee1k- related activity (Figure 3.5 E-H).
3.3.3 M6620 abrogates G2/M arrest following cisplatin treatment
It has been widely reported that ERCC1 deficient cells strongly arrest in G2/M
phase following treatment with DNA crosslinking agents. We next asked what effects
M6620 had on cell cycle arrest and checkpoint activation in a model of platinum
tolerance with ERCC1 deficiency. As we suspected that ATR inhibition in combination
with cisplatin was leading to enhanced DNA damage compared to cisplatin alone, we
hypothesized that combination treatment would lead to increased cell cycle arrest in
G2/M phase. To test this hypothesis, we treated H1299 wildtype and ERCC1 knockout
cells with 1 mol/L cisplatin, 1 mol/L M6620, or combination and monitored cell cycle
profiles by flow cytometry at ~20 hours post-treatment. In H1299 wildtype cells we
observed mild increases in G2/M arrest following treatment with cisplatin or combination
ATRi and cisplatin (Figure 3.6 A). Consistent with previously reported observations,
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Figure 3.6 ATR inhibition abrogates G2/M arrest following platinum treatment. A,
Cell cycle profiles following cisplatin and ATR inhibitor treatment in H1299 isogenic cells.
B, Cell cycle profiles following cisplatin and ATR inhibitor treatment ± 200 ng/mL
nocodazole. C, Cell cycle profiles over time after thymidine block in H1299 isogenic cells
treated with cisplatin, ATR inhibitor, or combination. One experiment is presented. All
cell cycle experiments were performed twice.
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treatment of H1299 ERCC1 knockout cells with cisplatin led to G2/M arrest, but strikingly,
combination treatment led to fewer cells arresting at G2/M (Figure 3.6 A).
While we observed fewer cells arresting in G2/M with combination treatment, we
also observed that the G1 peak broadened and thought it possible that either ATR
inhibition was leading to arrest in S-phase or that ATR inhibition was leading to bypass
of the G2/M cell cycle checkpoint. To test which of these possibilities was the case, we
performed the same treatments and monitored cell cycle profiles in the presence or
absence of 200 ng/mL nocodazole. In the presence of nocodazole, all treatment groups
strongly arrested at G2/M which indicated that ATR inhibition was not leading to S-phase
arrest but was leading to bypass of the G2/M cell cycle checkpoint (Figure 3.6 B).
To further understand these events, we synchronized cells with a double
thymidine block and monitored progression through the cell cycle following treatment at
the 4-, 22-, and 46-hour time points (Figure 3.6 C). In H1299 ERCC1 knockout cells, we
observed that cisplatin-treated cells arrested strongly at G2/M phase at the 4-hour and
22-hour time points, but that cells completely recovered from this G2/M arrest by 46
hours post-treatment. In the H1299 wildtype and ERCC1 knockout cells, we observed
that treatment groups containing M6620 entered the subsequent G1 phase at a much
faster rate than untreated and cisplatin-treated groups (Figure 3.6 C). We also observed
that cells tended to accumulate and progress much more slowly through the subsequent
S-phase possibly indicating that cells were requiring more time for DNA replication
possibly due to the persistence of replication-associated damage from the previous
round of the cell cycle. We detected increases in induction of apoptotic cell death in
H1299 WT and ERCC1 knockout cells at 48 hours post-treatment by PE Annexin-V/7AAD staining (Figure 3.7 A). Additionally, we saw increases in -galactosidase staining
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Figure 3.7 Induction of apoptosis and senescence following treatment in H1299
isogenic cell lines. A. Apoptotic cell death detected ~48 hours after treatment with 1
mol/L cisplatin, 1 mol/L M6620 or combination by 7AAD and PE-Annexin V staining
and flow cytometry. Data is representative of two individual experiments. B. bgalactosidase staining in H1299 wildtype and knockout cells six days after treatment with
500 nmol/L cisplatin, 500 nmol/L M6620 or combination. Data is representative of two
individual experiments.
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in ERCC1 knockout cells following cisplatin and ATRi treatment 6 days following
treatment consistent with induction of cellular senescence (Figure 3.7 B). We reason that
cell fate after combination treatment is a cell-specific phenomenon that may depend
upon the amount of DNA damage accumulated during the first round of DNA replication.
3.3.4 Dual treatment with cisplatin and M6620 enhances H2AX formation and
induces replication catastrophe
Next, we tested whether combination treatment induced DNA double-strand
breaks in platinum tolerant, ERCC1-deficient cells. Approximately 16 hours posttreatment with cisplatin, M6620 or combination, cells were fixed and stained for H2AX
foci to monitor formation of DNA double-strand breaks. Cisplatin-treated cells had very
few H2AX foci above untreated cells consistent with our previously published data (30).
Additionally, the addition of the ATR inhibitor alone did not dramatically increase
formation of DNA double-strand breaks. Strikingly, the combination treatment led to
substantial increases in H2AX foci (Figure 3.8 A). Thus, ATR inhibition potentiated DNA
double-strand break formation or persistence after cisplatin treatment in platinumtolerant, ERCC1-deficient cells. As ATR activity has been shown to be critical for
suppressing replication catastrophe after DNA damage by limiting depletion of available
RPA pools, we asked whether combination treatment was inducing chromosome
pulverization (195). We generated metaphase spreads following chronic treatment with
cisplatin, ATRi, or cisplatin and ATRi and observed that platinum tolerant, ERCC1deficient cells were more susceptible to chromosome pulverization than the parental
ERCC1 wildtype cells with combination treatment (Figure 3.8 B & C). Next, we asked
whether chromosome pulverization with combination treatment was specifically linked to
defects associated with DNA replication. To answer this question, we treated cells with
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Figure 3.8 Effects of dual cisplatin and M6620 treatment on DNA double strand
break formation and induction of chromosome pulverization. A. H2AX staining by
immunofluorescence ~22 hours after treatment in H1299 ERCC1 knockout cells. B.
Representative metaphase spreads prepared from H1299 wildtype and ERCC1
knockout cells ~48 hours following treatment. C. Quantification of chromosome
pulverization in H1299 wildtype and ERCC1 knockout cells following treatment. D.
Representative images showing colocalization of EdU with pulverized chromosomes in
H1299 ERCC1 knockout cells treated with cisplatin and M6620. E. Quantification of
normal metaphases (NM) and chromosome pulverization (i.e. replication catstrophe
(RC)) and colocalization with EdU staining in untreated and cisplatin + M6620 treated
H1299 ERCC1 knockout cells. All experiments were performed three times. Error bars
represent ± S.D. * p<0.05; ** p<0.01.
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cisplatin for two hours, pulse labeled with EdU to label actively replicating cells, followed
by ATR inhibition for four hours. 48 hours post-treatment metaphase spreads were
generated and stained for EdU to identify whether chromosome pulverization was
enriched for cells that were actively replicating DNA at the time of ATR inhibition.
Compared to untreated cells, ERCC1 knockout cells that were positive for chromosome
pulverization were significantly enriched for EdU positivity, indicating that chromosome
pulverization (i.e. replication catastrophe) with combination treatment was specifically
linked to inhibition of ATR during S-phase (Figure 3.8 D & E).
3.3.5 Combination treatment induces micronuclei formation associated with
H2AX and cGAS binding
Platinum in combination with immune checkpoint blockade inhibitors have
become first-line treatment for the majority of non-small cell lung cancer patients. Next
we asked whether combination treatment led to increased micronuclei formation in
platinum tolerant, ERCC1 knockout cells and whether increased micronuclei were
associated with DNA double-strand breaks and activation of the innate immune
response. Activation of the innate immune response by cytosolic DNAs via cGAS-STING
pathway has also been shown to influence response to immune checkpoint blockade
inhibitors including anti-CTLA4 and anti-PD-L1 therapies (196, 197). To address this
question, we monitored formation of micronuclei in H1299 wildtype and ERCC1
knockout cells following treatment with cisplatin, ATRi, or combination treatment. While
we did not observe differences between wildtype and ERCC1 knockout cells in terms of
the number of cells positive for micronuclei formation, we did see a significant difference
between ERCC1 wildtype and knockout cells when we assessed the number of cells
harboring greater than two micronuclei (Figure 3.9 A & B). In the context of DNA
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Figure 3.9 Detection of micronuclei following treatment in H1299 wildtype and
ERCC1 knockout cell lines. A. Quantification of the total percent of micronucleated
cells ~48 hours after treatment. Data presented as the average of three independent
experiments ± S.D. B. Quantification of the number of cells positive for >2 micronuclei
~48 hours after treatment. Data presented as the average of three independent
experiments ± S.D. C. Immunofluorescence reveals colocalization of micronuclei with
gH2AX in H1299 ERCC1 knockout cells following combination treatment. Data are
representative from two independent experiments. D. Detection of gH2AX and cGAS
colocalization with micronuclei in H1299 ERCC1 knockout cells treated with cisplatin and
M6620. Data are representative from two independent experiments.
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damage, it was previously shown that micronuclei largely stain positive for H2AX (196).
Staining of micronuclei for H2AX in H1299 ERCC1 knockout cells revealed that
micronuclei are associated with DNA double-strand breaks (Figure 3.9 C). These
micronuclei were also capable of being bound by the innate immunomodulatory factor
cGAS, which could indicate that combination treatment may also have positive impacts
in terms of modulating responses to immunotherapy (Figure 3.9 D).
3.4 Discussion
Setbacks in the clinical implementation of ERCC1 expression as a first-in-class
biomarker for determining which lung cancer patients will benefit most from platinumbased chemotherapy suggest that our current understanding of its predictive power
remain unclear. Our recent work identified p53 status as a partial confounding variable in
clinical evaluations of ERCC1 as a platinum biomarker (30). Patients with lung tumors
harboring low ERCC1 and wildtype p53 had a 50% increase in overall survival compared
to those with ERCC1high/p53WT tumors. Conversely, there was no overall survival benefit
for patients whose tumors had low ERCC1 compared to high ERCC1 when p53 was
mutated. With these previous observations in mind, we show that ATR inhibition by
M6620 represents a potential therapeutic strategy for overcoming tolerance to platinumbased chemotherapy in tumors harboring low ERCC1 and a functional deficiency in p53.
We identified that ATR activity was responsible for tolerance to DNA crosslinks
induced by cisplatin in a cell line model of platinum tolerance with ERCC1 deficiency.
While a model of cisplatin hypersensitivity could not be further sensitized to cisplatin by
ATR inhibition, a model of cisplatin tolerance with ERCC1 deficiency could be sensitized
to cisplatin by ATR inhibition in a synergistic manner (approximately ten-fold in vitro).
These data appear to suggest that at least one reason for platinum tolerance with
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ERCC1 deficiency is likely increased replication fork protection. Assessing cell cycle
profiles after combination treatment revealed that ATR inhibition by M6620 leads to
abrogation of the G2/M cell cycle checkpoint after cisplatin treatment. Similar
observations were recently made in BRCA mutant tumors when treated with the ATR
inhibitor AZD6738 in combination with olaparib (198). Additionally, in cell synchronization
studies, we observed that ATR inhibited cells enter the subsequent G1 phase much
faster than untreated control cells which could also be related to a deregulated S/G2
checkpoint controlled by ATR which was recently described (199). After this bypass of
the G2/M checkpoint, we detected accumulation of cells in the subsequent S-phase,
likely indicating the presence of persistent DNA damage from the previous round of DNA
replication. In terms of sensitization of platinum-tolerant ERCC1 knockout cells to
cisplatin by ATR inhibition, one possibility would be that G2/M arrest following cisplatin
treatment may be critical for promoting ERCC1-independent repair thus limiting the
amount of persistent DNA damage detected in the subsequent G1 phase and ultimately
during the second round of DNA replication; thus, ATR inhibition may block this G 2/M
arrest and sensitize these cells to cisplatin. Alternatively, ATR inhibition during S-phase
may lead to enhanced replication-associated DNA damage associated with cisplatin and
it is these effects in combination with bypass of the G2/M checkpoint that is critical for
promoting cisplatin sensitivity in the absence of ERCC1 and p53.
In platinum tolerant ERCC1-deficient cells, dual treatment coincided with
substantial increases in DNA double-strand breaks as shown by H2AX staining.
Subsequent analysis revealed that dual treatment led to increased rates of replication
catastrophe as shown by quantification of chromosome pulverization. Increased
amounts of DNA double-strand breaks were also linked to increased micronuclei
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formation, an activator of the innate immune response in H1299 ERCC1 knockout cells.
These micronuclei were more numerous in ERCC1 knockout cells, were associated with
DNA double strand breaks, and were capable of being bound by the innate immunomodulatory factor, cGAS. Micronuclei formation has become a well-established marker
for activation of the innate immune response that is associated with increased PD-L1
expression and may positively impact response of tumors to immunotherapy (196, 200,
201). Similar observations with micronuclei formation in the context of ERCC1 deficiency
and PARP inhibition were recently published (202). In that context, increased
micronuclei formation was associated with increased membranous PD-L1 expression,
activation of IFN signaling mediated by cGAS-STING, and secretion of CCL5 (202).
These observations have important implications for lung cancer therapy as first-line
treatment for ~85% of advanced non-small cell lung cancer patients includes a platinumbased agent in combination with anti-PD-L1 therapy.
While three ATR inhibitors are currently in clinical trials, M6620 was the first to
enter Phase II trials. This highly selective inhibitor of ATR kinase activity has shown
promising activity in two Phase I studies. Results from a Phase I study combining
topotecan with M6620 in 21 patients with advanced solid tumors who had failed at least
one prior line of therapy showed two partial responses and eight patients with stable
disease (203). Strikingly, three of five small cell lung cancer patients with platinumrefractory disease had durable clinical benefit from M6620 and topotecan combination
therapy. Additionally, preliminary results from a Phase I study combining cisplatin and
M6620 in triple negative breast cancers showed an objective response rate of nearly
39% and the disease control rate was approximately 72% (204).Preliminary clinical trial
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data suggests promising activity of M6620 in combination with cytotoxic chemotherapy in
a subset of patients, particularly those with deficiencies in DNA repair associated genes.
In summary, we recently identified p53 status as a confounding variable in
clinical assessments of ERCC1 status as a first-in-class biomarker for predicting
response to platinum-based chemotherapy. Building upon this work, we have identified
ATR kinase activity as essential for tolerance to platinum-based chemotherapy in
ERCC1-deficient/p53-deficient tumors and propose that these specific patients would
benefit from combination treatment with M6620, a platinum analogue, and potentially
anti-PD-L1 therapy.
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CHAPTER 4- CONCLUSIONS
With its long history of being investigated as a biomarker for response to
platinum-based chemotherapy, our understanding of the biology of ERCC1 in human
tumors continues to evolve. Probably the best example of another set of factors that has
had a similar trajectory in terms of scientific advances would be BRCA1 and BRCA2 in
the context of PARP inhibition. While it was initially discovered that BRCA1 and BRCA2
mutant cancers respond exceptionally well to PARP inhibition, resistance to this therapy
eventually occurs. Subsequent and ongoing research efforts have since identified
multiple mechanisms of resistance to PARP inhibitors despite mutations in BRCA1 and
BRCA2, including gene reversion, increased replication fork stability and restored
homologous recombination. In a similar way, preclinical data showed that ERCC1
expression was strongly associated with response to platinum-based chemotherapy and
a number of retrospective studies validated those in vitro observations. However, larger
studies including an international, randomized Phase III clinical trial did not recapitulate
those prior findings. These differences appeared to suggest that confounding variables
related to either detection of ERCC1 or unknown resistance mechanisms may have
influenced the ability of ERCC1 expression to predict patient response to platinum-based
chemotherapy.
Chapter 2: Prior to the data described in this work, three main variables were
thought to have influenced previous clinical studies of ERCC1: 1) Problems with
antibody specificity for ERCC1 which impacted immunohistochemical detection of the
protein; 2) Unoptimized cutoff for determining mRNA high vs. low ERCC1 tumors; and 3)
ERCC1 splice variant expression of which only one of four splice variants is functional in
DNA repair. In addition to these technical issues, our work described in Chapter 2 led to
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the observation that ERCC1 deficiency does not always predispose to cisplatin
hypersensitivity but is likely dependent upon the genetic background of the tumor, e.g.
p53 status. Despite being thought to be absolutely required for repair of platinuminduced DNA damage, loss of ERCC1 does not appear to be strongly associated with
platinum sensitivity when p53 function is impaired in both cell line and retrospective
patient studies. Our general hypothesis for this phenomenon is that platinum treatment
leads to DNA damage and that in the absence of ERCC1 this leads to repair refractory
DNA double-strand breaks that trigger G2/M arrest. However, we showed that G2/M
arrest is not permanent and cells eventually escape into the subsequent G1 phase where
wildtype p53 is critical for sensing persistent DNA damage, triggering growth arrest, and
inducing apoptosis. In the absence of p53, there is loss of a functional G1 cell cycle
checkpoint, a reduction in apoptotic potential and the formation of an environment in
which alternative DNA repair mechanisms (likely error prone) can partially compensate
for loss of ERCC1/XPF activity. In support of these data, we observed that BRCA1 and
DNA-PK function appear to be critical for supporting tolerance to platinum in the
absence of ERCC1. Additionally, we found that timely entry into S-phase is also critical
pointing to the importance of events during DNA replication for maintaining platinum
tolerance in the absence of ERCC1.
Chapter 3: Because we found that events in S-phase were critical for supporting
platinum tolerance in the absence of ERCC1, we asked whether pharmacological
inhibition of the DNA damage kinase ATR could represent a viable strategy for
resensitizing these cells to platinum. ATR is an important factor involved in orchestrating
the processing of stalled replication forks, preserving replication fork stability, limiting
origin firing, and promoting repair of DNA double-strand breaks induced in a replication-
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dependent manner. Because of these critical functions, ATR has become an attractive
therapeutic target in multiple tumor types and three ATR inhibitors have entered clinical
trials. We found that platinum tolerant, ERCC1-deficient cells (p53 mutant/null) can be
exquisitely sensitized to platinum-based chemotherapy by the ATR inhibitor M6620. This
sensitization by M6620 was associated with increased DNA double-strand break
formation and chromosome pulverization possibly suggesting that in the absence of
ATR, stalled replication forks become unstable potentially mediated by RPA exhaustion
and leading to global replication fork collapse. In addition, combination treatment
induced micronuclei formation capable of being bound by the innate immunomodulatory
factor cGAS which can trigger activation of the innate immune response. Thus, an ATR
inhibitor not only could influence sensitivity of ERCC1 deficient tumors to cisplatin, but
could also positively regulate response to immune checkpoint blockade inhibitors when
given in combination with platinum-based chemotherapy in DNA repair deficient cells.
Remaining Questions: In conclusion, a number of subsequent scientific
questions arising from our results warrant further investigation. First, it is unclear
whether p53 status is sufficient for or whether it is only a necessary component of the
phenotype of platinum tolerance in the absence of ERCC1. Our data utilizing isogenic
cell lines appeared to suggest that other events beside loss of functional p53 likely play
a role in this process, e.g. increased replication fork stability or increased alternative
mechanisms of repair.
Second, it is also unclear whether loss of other DNA repair factors leads to a
similar differential phenotype that depends upon p53, e.g. XPA, BRCA2, or FANCD2,
although some evidence suggests that differential phenotypes exist with loss of various

115

Fanconi Anemia proteins and endonucleases involved in interstrand crosslink repair
(171, 190).
Thirdly, the identification that timely entry into S-phase and ultimately ATR
function are critical for supporting platinum tolerance in the absence of ERCC1 suggests
that replication fork stability/protection likely play a role in facilitating these events. It will
be important to clarify specifically whether this is the case as well as to examine in more
detail whether p53 is associated with differences in basal capacity for replication fork
protection between the cisplatin hypersensitive/tolerant ERCC1 deficient cell lines. It is
possible that in the absence of ERCC1 replication forks approach an intrastrand
platinum-DNA adduct and stall. This stalling leads to ATR recruitment which may
facilitate recruitment of translesion polymerases to the stalled forks and allow for bypass
past these adducts which represent up to ~90% of all platinum-DNA lesions. ATR would
also support replication fork stability by limiting origin firing and suppressing RPA
exhaustion which in turn would prevent accumulation of aberrant DNA double-strand
breaks. However, in the absence of ATR, stalled forks accumulate which can lead to fork
collapse and breakage induced by random endonucleases consistent with the pulverized
chromosomes observed with combination cisplatin and ATRi treatment. Further clarifying
these events will provide insight from a mechanistic perspective as to how ATR inhibition
sensitizes platinum tolerant, ERCC1-deficient cells to cisplatin.
Fourth, key to identifying ways to sensitize these platinum tolerant tumors to
cisplatin will be to identify what DNA structures are produced in the absence of ERCC1
and describe how alternative DNA repair occurs. One way to test this could be to look at
global changes in the proteome with specific interest in DNA repair factors that may be
upregulated after treatment in ERCC1 deficient cells. A second way to get at which DNA
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repair pathways are involved in partially compensating for loss of ERCC1 after cisplatin
treatment would be to look at mutation profiles in cell lines after treatment since patterns
can be associated with particular DNA repair events, (e.g. deletions, specific types of
mutation profiles, rearrangements, chromosome loss, etc.). A genome-wide CRISPR or
RNAi screen could also be appropriate in this instance and could identify key factors for
further study that may be necessary for promoting ERCC1-independent platinum-DNA
adduct repair. These studies could be critical for further developing novel targets to
sensitize platinum tolerant, ERCC1-deficient tumors to platinum-based chemotherapy.
Finally, when we combined an ATR inhibitor with cisplatin in ERCC1 deficient
cells, we observed bypass of G2/M cell cycle arrest. Subsequent studies revealed that
combination treatment induced DNA double-strand breaks and ultimately led cells to
undergo apoptosis or senescence. However, we also observed a large number of cells
that entered another round of S-phase where a large number of cells accumulated as
shown by cell cycle experiments. While cell fate is probably dependent upon the extent
of DNA damage induced during the previous round of DNA replication, it is unclear what
the consequences are of a second round of DNA replication in this context. For example,
is a second round of DNA replication important for chromosome pulverization or is
chromosome pulverization completely dependent upon the first round of DNA
replication? Another question is what effects does persistent DNA damage from the first
round of the cell cycle have once cells re-enter another S-phase: Is there processing that
makes these persistent lesions especially toxic during a second round of S-phase? A
complete characterization of the events during the second round of DNA replication
could provide insight into the mechanism of sensitization to cisplatin by ATR inhibition in
DNA repair deficient cells.
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We have identified a novel phenotype of platinum resistance in ERCC1 deficient
cells and patient tumors that may have important ramifications for the future clinical
development of ERCC1 as a platinum biomarker or therapeutic target. The identification
of ATR as a target for potent sensitization of platinum tolerant, ERCC1-deficient cells
supports the idea that replication-dependent events are critical for platinum tolerance in
this specific context and further clinical studies may be warranted.
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ABSTRACT
NOVEL INSIGHTS INTO THE USE OF ERCC1 AS A BIOMARKER FOR RESPONSE
TO PLATINUM-BASED CHEMOTHERAPY IN LUNG CANCER
by
JOSHUA R. HEYZA
August 2019
Advisor: Steve M. Patrick, Ph.D.
Major: Cancer Biology
Degree: Doctor of Philosophy
ERCC1/XPF is a DNA endonuclease with variable expression in primary tumor
specimens, and has been investigated as a predictive biomarker for efficacy of platinumbased chemotherapy in non-small cell lung cancers where up to 30-60% of tumors
harbor low to undetectable ERCC1 expression. The failure of an international,
randomized Phase III clinical trial utilizing ERCC1 expression to predict response to
platinum-based chemotherapy suggests additional mechanisms underlying the basic
biology of ERCC1 in the response to platinum-DNA damage remain unknown. In this
work, we aimed to characterize a panel of ERCC1 knockout cell lines generated via
CRISPR-Cas9 where we identified a synthetic viable phenotype in response to
intestrand crosslinks (ICLs) with ERCC1 deficiency. Characterization of these ERCC1
knockout cell lines revealed loss of ERCC1 hypersensitized cells to cisplatin when
wildtype (WT) p53 is retained, while there was only modest sensitivity in cell lines that
were p53mutant/null. Additionally, when p53 was disrupted by CRISPR-Cas9 (p53*) in
ERCC1 knockout/p53WT cells, there was reduced apoptosis and increased viability after
platinum treatment. These results were recapitulated in two patient data sets utilizing
p53 mutation analysis and ERCC1 expression to assess Overall Survival. We also show

165

that kinetics of ICL-repair differed between ERCC1 knockout/p53WT and ERCC1
knockout/p53* cells. Finally, we provide evidence that cisplatin tolerance in the context
of ERCC1 deficiency relies on DNA-PKcs and BRCA1 function as well as timely entry
into S phase suggesting that replication dependent mechanisms are likely involved in
promoting platinum tolerance.
Building upon these observations, we utilized our established lung cancer cell
line models of ERCC1 deficiency to find that platinum tolerance with ERCC1 deficiency
relies upon ATR signaling. ATR inhibition by M6620 selectively and synergistically
enhanced platinum sensitivity of platinum tolerant ERCC1-deficient cells. Interestingly,
this increased sensitivity was independent of Chk1 and Wee1 kinase inhibition,
suggesting that ATR may support platinum-tolerance in the absence of ERCC1 by
suppressing global replication fork collapse independent of activating the G2/M cell cycle
checkpoint. Additionally, dual treatment led to increased formation of DNA double strand
breaks and was associated with increased levels of pulverized chromosomes.
Combination treatment was also associated with increased micronuclei formation which
were capable of being bound by the innate immunomodulatory factor, cGAS, suggesting
that combination platinum and ATRi treatment may also enhance response to
immunotherapy in ERCC1-deficient tumors harboring a p53 mutation.
Our findings implicate p53 as a potential confounding variable in clinical
assessments of ERCC1 as a platinum biomarker via promoting an environment in which
error-prone mechanisms of ICL-repair may be able to partially compensate for loss of
ERCC1. Additionally, results of this study have led to the identification of a feasible
therapeutic strategy combining M6620 with cisplatin to overcome platinum tolerance in
ERCC1-deficient, p53-mutant lung cancers.
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